Search Result
Results for "
cardiovascular
" in MCE Product Catalog:
2975
Inhibitors & Agonists
18
Biochemical Assay Reagents
363
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
-
- HY-107337
-
-
- HY-90009B
-
-
- HY-135601
-
-
- HY-N11099
-
-
- HY-103314
-
-
- HY-N6617
-
-
- HY-W104304
-
-
- HY-14936
-
|
Sofigatran
MCC-977
|
Thrombin
|
Cardiovascular Disease
|
|
Sofigatran (MCC-977) is an orally active factor IIa (thrombin) inhibitor, acts as an anticoagulant. Sofigatran is used for the research of cardiovascular disease.
|
-
- HY-14838
-
-
- HY-14838A
-
-
- HY-112071
-
-
- HY-17464
-
-
- HY-143221
-
|
AS-Inclisiran
|
Ser/Thr Protease
|
Cardiovascular Disease
|
|
AS-Inclisiran is the antisense of Inclisiran. Inclisiran (ALN-PCSsc) is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9. Inclisiran can be used for hyperlipidemia and cardiovascular disease (CVD) research.
|
-
- HY-N11081
-
|
Hexanorcucurbitacin D
|
Others
|
Cardiovascular Disease
|
|
Hexanorcucurbitacin D is a cucurbitacin. Hexanorcucurbitacin D can be isolated from Trichosanthes cucumeroides roots. Hexanorcucurbitacin D can be used for the research of cardiovascular disease (CVD).
|
-
- HY-132591
-
-
- HY-124063
-
-
- HY-B0232
-
-
- HY-141552
-
|
FC9402
|
Others
|
Cardiovascular Disease
|
|
FC9402 is a potent and selective sulfide quinone oxidoreductase (SQOR) inhibitor extracted from patent WO 2020/146636 A1. FC9402 attenuates TAC-induced cardiomyocyte hypertrophy and left ventricle (LV) fibrosis. FC9402 can be used for cardiovascular regulation.
|
-
- HY-119515
-
|
Denopamine
(R)-(-)-Denopamine; TA-064
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Denopamine ((R)-(-)-Denopamine) is an orally active, selective β1-adrenergic agonist. Denopamine prolongs survival in a murine model of congestive heart failure induced by viral myocarditis: suppression of tumor necrosis factor-α production in the heart. Cardiovascular effects.
|
-
- HY-150223
-
-
- HY-112070
-
-
- HY-112094S
-
-
- HY-N10151
-
|
Notoginsenoside R3
|
Others
|
Cardiovascular Disease
|
|
Notoginsenoside R3 is an active principle components of P. notoginseng. Notoginsenoside R3 act as a signaling molecule that is associated with various physiological effects. P. notoginseng and its components are used as traditional Chinese medicine for cardiovascular disease.
|
-
- HY-14252A
-
|
Milrinone lactate
Win 47203 lactate
|
Others
|
Cardiovascular Disease
|
|
Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock.
|
-
- HY-106616
-
|
Muzolimine
BAY-g 2821; Edrul
|
Others
|
Cardiovascular Disease
|
|
Muzolimine (BAY-g 282) is a slow and long lasting diuresis agent. Muzolimine produces a diuresis in the loop of Henle and also shows anti-hypertensive effects. Muzolimine can be used for the research of cardiovascular disease.
|
-
- HY-120577
-
|
BA 41899
|
Others
|
Cardiovascular Disease
|
|
BA 41899 is a purely calcium-sensitizing agent. BA 41899 is completely devoid of phosphodiesterase (PDE) III inhibitory activity or any other known inotropic mechanism. BA 41899 can be used for the research of cardiovascular diseases, such as congestive heart failure (CHF).
|
-
- HY-131515
-
-
- HY-145584
-
-
- HY-P99505
-
-
- HY-148836
-
|
c-Myc inhibitor 6
|
c-Myc
|
Cancer
Infection
Cardiovascular Disease
|
|
c-Myc inhibitor 6 (compound A102) is a c-Myc inhibitor. c-Myc inhibitor 6 decreases cancer cell viability and degrades c-Myc protein. c-Myc inhibitor 6 can be used for the research of c-Myc imbalance, such as cancer, cardiovascular diseases, and viral infection.
|
-
- HY-B0835
-
|
Fenobucarb
|
Apoptosis
|
Neurological Disease
Cardiovascular Disease
|
|
Fenobucarb is a carbamate insecticide. Fenobucarb induces zebrafish developmental neurotoxicity through pathways involved in inflammation, oxidative stress, degeneration and apoptosis. Fenobucarb is a possible risk factor to cardiovascular and cerebrovascular systems in animals.
|
-
- HY-12176B
-
|
Aliskiren fumarate
CGP 60536 fumarate; CGP60536B fumarate; SPP 100 fumarate
|
Renin
Autophagy
|
Cancer
Cardiovascular Disease
|
|
Aliskiren fumarate is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren fumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
|
-
- HY-12176
-
|
Aliskiren
CGP 60536; CGP60536B; SPP 100
|
Renin
Autophagy
|
Cardiovascular Disease
Cancer
|
|
Aliskiren is an orally active, highly potent and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
|
-
- HY-142697
-
|
SGC agonist 1
|
Others
|
Cardiovascular Disease
|
|
SGC agonist 1 is a potent agonist of soluble guanylate cyclase (SGC). SGC agonist 1 improves solubility combined with high cell permeability. SGC agonist 1 has the potential for the research of cardiovascular disease (extracted from patent WO2016030354A1, compound 18A).
|
-
- HY-124756
-
|
SBI-425
|
Phosphatase
|
Cardiovascular Disease
|
|
SBI-425 is an orally active and potent TNAP (tissue-nonspecific alkaline phosphatase) inhibitor (IC50=16 nM). SBI-425 inhibits TNAP in the vasculature, improving cardiovascular parameters and survival.
|
-
- HY-106950S1
-
-
- HY-A0176
-
-
- HY-145581
-
|
Mitiperstat
AZD4831
|
Glutathione Peroxidase
|
Cardiovascular Disease
|
|
Mitiperstat (AZD4831) is the potent inhibitor of myeloperoxidase (MPO). Mitiperstat is particularly useful in the research of prophylaxis of cardiovascular disorders such as heart failure and coronary artery disease related conditions (extracted from patent US20160152623A1).
|
-
- HY-139486
-
|
AM-8123
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
AM-8123 is an orally active and potent APJ agonist. AM-8123 inhibits Forskolin-stimulated cAMP production and promotes Gα protein activation. AM-8123 can be used for the research of cardiovascular disease.
|
-
- HY-N10742
-
|
Maritimetin
|
Reactive Oxygen Species
|
Cardiovascular Disease
|
|
Maritimein is an aurone that can be isolated from Coreopsis tinctoria. Maritimein shows strong diphenyl(2,4,6-trinitrophenyl)iminoazanium (DPPH) radical-scavenging activity with an IC50 value of 4.12 μM. Maritimein can be used for the research of cardiovascular disease.
|
-
- HY-P1298
-
|
Sauvagine
|
CRFR
|
Endocrinology
Neurological Disease
Cardiovascular Disease
|
|
Sauvagine, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine is effective at releasing ACTH from rat pituitary cells. Sauvagine possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.
|
-
- HY-12176A
-
|
Aliskiren hydrochloride
CGP 60536 hydrochloride; CGP60536B hydrochloride; SPP 100 hydrochloride
|
Renin
Autophagy
|
Cancer
Cardiovascular Disease
|
|
Aliskiren (CGP 60536; CGP60536B; SPP 100) hydrochloride is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hydrochloride can be used for the research of hypertension, cardiovascular diseases and cancer cachexia -.
|
-
- HY-123268
-
|
Ro 363
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Ro 363, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. RO 363 is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.
|
-
- HY-123268A
-
|
Ro 363 hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Ro 363 hydrochloride, an effective inotropic stimulant, is a potent and highly selective β1-adrenoceptor agonist. Ro 363 hydrochloride is a cardiovascular modulator that reduces diastolic blood pressure and pronounces increases in myocardial contractility.
|
-
- HY-151203
-
|
PKG1α activator 3
|
Others
|
Cardiovascular Disease
|
|
PKG1α activator 3 is a PKG1α activator (EC50 basal/partial=13/0.52 μM). PKG1α activator 3 shows anti-proliferative effects to smooth muscle cell, and can be used in cardiovascular disease research.
|
-
- HY-P1913
-
-
- HY-110237
-
|
BX430
|
P2X Receptor
Calcium Channel
|
Cardiovascular Disease
|
|
BX430 is a potent and selective noncompetitive allosteric human P2X4 receptor channels antagonist with an IC50 of 0.54 μM. BX430 has species specificity. BX430 is used for chronic pain and cardiovascular disease.
|
-
- HY-P99560
-
|
Tadocizumab
C4G1; YM-337
|
Integrin
|
Cardiovascular Disease
|
|
Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research.
|
-
- HY-148212
-
-
- HY-P1298A
-
|
Sauvagine TFA
|
CRFR
|
Endocrinology
Neurological Disease
Cardiovascular Disease
|
|
Sauvagine TFA, a 40-amino-acid neuropeptide from the skin of the frog, is a mammalian CRF agonist. Sauvagine TFA is effective at releasing ACTH from rat pituitary cells. Sauvagine TFA possesses a number of pharmacological actions on diuresis, the cardiovascular system and endocrine glands.
|
-
- HY-12177
-
|
Aliskiren hemifumarate
CGP 60536 hemifumarate; CGP60536B hemifumarate; SPP 100 hemifumarate
|
Renin
Autophagy
|
Cardiovascular Disease
Cancer
|
|
Aliskiren (CGP 60536; CGP60536B; SPP 100) hemifumarate is an orally active and selective renin inhibitor, with IC50 of 1.5 nM. Aliskiren hemifumarate can be used for the research of hypertension, cardiovascular diseases and cancer cachexia.
|
-
- HY-P1913A
-
-
- HY-16952A
-
|
Bepridil hydrochloride hydrate
(±)-Bepridil hydrochloride hydrate; Org 5730 hydrochloride hydrate
|
Calcium Channel
|
Cardiovascular Disease
|
|
Bepridil hydrochloride hydrate ((±)-Bepridil hydrochloride hydrate) is a non-selective, long-acting Ca + channel antagonist and Na +, K + channel inhibitor, with antianginal and type I antiarrhythmic effects. Bepridil hydrochloride hydrate also acts as a cardiac Na +/Ca2 + exchange (NCX1) inhibitor. Bepridil hydrochloride hydrate can be used for the research of cardiovascular disorders.
|
-
- HY-143294
-
|
sEH inhibitor-2
|
Epoxide Hydrolase
|
Cardiovascular Disease
|
|
sEH inhibitor-2 (compound 5l) is an orally active (predicted percentage absorption: 71.2-88.4%) soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 0.9 nM. sEH inhibitor-2 can maintain epoxyeicosatrienoic acids (EETs) serum level in high concentrations. sEH inhibitor-2 can be used in study of cardiovascular protection.
|
-
- HY-19644
-
|
GSK2256294A
GSK 2256294
|
Epoxide Hydrolase
|
Cardiovascular Disease
|
|
GSK2256294A (GSK 2256294) is a selective and orally active inhibitor of soluble epoxide hydrolase (sEH). GSK2256294A inhibits recombinant human sEH, rat sEH orthologs and murine sEH orthologs with IC50s of 27, 61 and 189 pM, respectively. GSK2256294A can be used for the research of chronic obstructive pulmonary disease (COPD) and cardiovascular disease.
|
-
- HY-W009749
-
|
L-Cystathionine
|
Endogenous Metabolite
Apoptosis
|
Cardiovascular Disease
|
|
L-Cystathionine is a nonprotein thioether and is a key amino acid associated with the metabolic state of sulfur-containing amino acids. L-Cystathionine protects against Homocysteine-induced mitochondria-dependent apoptosis of vascular endothelial cells (HUVECs). L-Cystathionine plays an important role in cardiovascular protection.
|
-
- HY-N8086
-
-
- HY-N8087
-
-
- HY-P0203
-
|
α-CGRP, rat
|
CGRP Receptor
|
Metabolic Disease
Inflammation/Immunology
Cardiovascular Disease
|
|
α-CGRP, rat, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP, rat can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP, rat has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies.
|
-
- HY-107546
-
|
CFM 1571 hydrochloride
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
CFM 1571 hydrochloride is the stimulator of the nitric oxide receptor, soluble guanylate cyclase (sGC) with an EC50 and IC50 of 5.49 μM and 2.84 μM, respectively. Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). CFM 1571 hydrochloride has the potential for the research of cardiovascular and other diseases.
|
-
- HY-142698
-
|
SGC agonist 2
|
Others
|
Cardiovascular Disease
|
|
SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031).
|
-
- HY-B0143A
-
|
Niacin hydrochloride
Nicotinic acid hydrochloride; Vitamin B3 hydrochloride
|
Endogenous Metabolite
Apoptosis
|
Cancer
Metabolic Disease
Cardiovascular Disease
|
|
Niacin (Vitamin B3; Nicotinic acid) hydrochloride is an orally active B3 vitamin that is an essential nutrient for humans. Niacin hydrochloride plays a key role in energy metabolism, cell signaling cascades regulating gene expression and apoptosis. Niacin hydrochloride is also used in the study of cardiovascular diseases.
|
-
- HY-P0203A
-
|
α-CGRP, rat TFA
|
CGRP Receptor
|
Metabolic Disease
Inflammation/Immunology
Cardiovascular Disease
|
|
α-CGRP, rat TFA, a neuropeptide (calcitonin gene-related peptide (CGRP)) mainly expressed in neuromuscular junction, is a potent vasodilator. α-CGRP, rat TFA can lead to a fall in blood pressure and an increase in heart rate by peripheral administration, also relax colonie smooth muscle. α-CGRP, rat TFA has the potential in cardiovascular, pro-inflammatory, migraine and metabolic studies.
|
-
- HY-143313
-
-
- HY-136584
-
|
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid
|
Others
|
Metabolic Disease
Cardiovascular Disease
|
|
2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a ketone compound extracted from patent WO2002030860A2, compound example II-9. 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid can be used for the research of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders.
|
-
- HY-143300
-
-
- HY-N0728
-
|
α-Linolenic acid
|
PI3K
Akt
|
Cancer
Cardiovascular Disease
|
|
α-Linolenic acid, isolated from Perilla frutescens, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer.
|
-
- HY-B0143
-
|
Niacin
Nicotinic acid; Vitamin B3
|
Autophagy
Endogenous Metabolite
|
Cancer
Metabolic Disease
Cardiovascular Disease
|
|
Niacin (Vitamin B3) is an orally active water-soluble B3 vitamin that is an essential nutrient for humans. Niacin (Vitamin B3) plays a key role in energy metabolism, cell signaling cascades regulating gene expression and apoptosis. Niacin (Vitamin B3) is also used in the study of cardiovascular diseases.
|
-
- HY-W062836
-
|
BAY 41-8543
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
BAY 41-8543 is an orally active, nitric oxide (NO)-independent stimulator of soluble guanylyl cyclase (sGC). BAY 41-8543 has vasodilator activity in the pulmonary and systemic vascular beds in the rat. BAY 41-8543 has antiplatelet effects and has the potential for cardiovascular diseases research.
|
-
- HY-121538
-
|
CUDA
|
Epoxide Hydrolase
PPAR
|
Cardiovascular Disease
|
|
CUDA is a potent inhibitor of soluble epoxide hydrolase (sEH), with IC50s of 11.1 nM and 112 nM for mouse sEH and human sEH, respectively. CUDA selectively increases peroxisome proliferator-activated receptor (PPAR) alpha activity. CUDA may be valuable for the research of cardiovascular disease.
|
-
- HY-146704
-
|
COX-2/sEH-IN-1
|
Epoxide Hydrolase
COX
|
Cardiovascular Disease
|
|
COX-2/sEH-IN-1 (Compound 9c) is an orally active, dual COX-2 and sEH (soluble epoxide hydrolase) inhibitor with IC50 values of 1.24 µM and 0.40 nM against COX-2 and sEH, respectively. COX-2/sEH-IN-1 shows improved anti-inflammatory activity and highly reduced cardiovascular risks.
|
-
- HY-122697
-
-
- HY-P9930
-
|
Evolocumab
AMG 145
|
Ser/Thr Protease
|
Metabolic Disease
Cancer
|
|
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases.
|
-
- HY-146731
-
|
PPARγ agonist 1
|
PPAR
|
Metabolic Disease
Cardiovascular Disease
|
|
PPARγ agonist 1 (compound 15) is a potent agonist of PPARγ. PPARγ agonist 1 shows high efficacy to activate hPPARγ without raising a full agonism and probably avoiding adverse effects. PPARγ agonist 1 has the potential for the research of cardiovascular diseases associated with metabolic disorders.
|
-
- HY-18725
-
-
- HY-147203
-
-
- HY-B0251
-
|
Eplerenone
Epoxymexrenone
|
Mineralocorticoid Receptor
Endogenous Metabolite
|
Cancer
Cardiovascular Disease
|
|
Eplerenone (Epoxymexrenone) is a selective, highly specific and orally active aldosterone blocker (SAB). Eplerenone also is a selective mineralocorticoid receptor antagonist (MRA) with IC50 value of 0.081 μM. Eplerenone can be used for the research of hypertension, atherosclerosis, chronic systolic heart failure (HF) and cardiovascular (CV).
|
-
- HY-18725A
-
-
- HY-126415
-
-
- HY-151483
-
|
TK-129
|
Histone Demethylase
|
Cardiovascular Disease
|
|
TK-129 is an orally active, low-toxicity, potent KDM5B inhibitor (with high affinity; IC50=44 nM). TK-129 exerts cardioprotective effects by inhibiting KDM5B and blocking the KDM5B-associated Wnt pathway. TK-129 reduces ang II-induced activation of cardiac fibroblasts in vitro and reduces isoprenaline-induced myocardial remodelling and fibrosis in vivo. TK-129 can be used in studies of cardiovascular disease.
|
-
- HY-125990
-
|
SLC13A5-IN-1
|
Sodium Channel
|
Metabolic Disease
Cardiovascular Disease
|
|
SLC13A5-IN-1 is a selective sodium-citrate co-transporter (SLC13A5) inhibitor. SLC13A5-IN-1 completely blocks the uptake of 14C-citrate with an IC50 value of 0.022 μM in HepG2 cells. SLC13A5-IN-1 has the potential for the treatment of metabolic and/or cardiovascular diseases. SLC13A5-IN-1 is extracted from patent WO2018104220A1, Compound I-5.
|
-
- HY-121392
-
-
- HY-131981
-
|
TP0586532
|
Bacterial
|
Infection
|
|
TP0586532 is a non-hydroxamate LpxC inhibitor (IC50=0.101 μM). TP0586532 as a compound with a low cardiovascular risk that is effective against K. pneumoniae, including resistant strains.
|
-
- HY-135773
-
-
- HY-W181102
-
|
NFAT Inhibitor-2
|
Others
|
Inflammation/Immunology
Neurological Disease
Cardiovascular Disease
|
|
NFAT Inhibitor-2 is a potent inhibitor of calcineurin NFAT signalling. Calcineurin is a serine/threonine protein phosphatase regulated by Ca2+ and calmodulin. NFAT Inhibitor-2 has the potential for the research of inflammatory disease, an autoimmune disorder, a cardiovascular disease, a neurodegenerative disease, a disease occurring with uncontrolled cell proliferation and/or differentiation, an angiogenesis-related disease, an allergy, anaphylaxis and alopecia (extracted from patent WO2016207212A1, compound 17).
|
-
- HY-14406A
-
-
- HY-P4153
-
|
Enlicitide chloride
MK-0616 chloride
|
Ser/Thr Protease
|
Cardiovascular Disease
|
|
Enlicitide chloride is a potent PCSK9 antagonist. Enlicitide chloride can be used for research of cardiovascular disease, e.g. atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.
|
-
- HY-135593
-
|
LY88074 analog 1
|
Others
|
Endocrinology
|
|
LY88074 analog 1 is a benzothiophene compound with nitrogen-containing non-basic side chains, Compound 26, extracted from patent EP0747380A1. LY88074 analog 1 is an agent for alleviating the symptoms of post-menopausal symptoms, such as osteoporosis, cardiovascular related pathological conditions, and estrogen-dependent cancer. LY88074 analog 1 can be used alone or in combination with estrogen or progestin.
|
-
- HY-40294
-
|
Indazole
|
Monoamine Oxidase
GSK-3
LRRK2
|
Cancer
Neurological Disease
Cardiovascular Disease
|
|
Indazole, also called isoindazole, a heterocyclic aromatic organic compound. Its derivatives display a broad variety of biological activities including anti-inflammatory, antibacterial, anti-HIV, antiarrhythmic, antifungal and antitumour properties. Indazole and its derivatives can be used for research of cancer, neurological disorders, cardiovascular diseases, gastrointestinal diseases.
|
-
- HY-U00398
-
-
- HY-U00044
-
-
- HY-147574
-
|
Axl-IN-7
|
TAM Receptor
|
Cancer
Inflammation/Immunology
Cardiovascular Disease
|
|
Axl-IN-7 (Chemie 22) is a potent AXL inhibitor. Axl-IN-7 can be used for Axl-related diseases research, for example cancers (such as acute myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glial tumors), renal disease, immune system disorders, and cardiovascular disease.
|
-
- HY-148475
-
-
- HY-U00034
-
-
- HY-147195
-
-
- HY-12376
-
|
BAY 41-2272
|
Guanylate Cyclase
|
Inflammation/Immunology
|
|
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research.
|
-
- HY-151616
-
|
sEH inhibitor-10
|
Epoxide Hydrolase
|
Metabolic Disease
Inflammation/Immunology
Cardiovascular Disease
|
|
sEH inhibitor-10 (Compound 37) is a selective soluble epoxide hydrolase (sEH) inhibitor (IC50=0.5 μM). sEH inhibitor-10 maintains high cycloeicosatrienoic acid (EETs) levels by inhibiting sEH, thereby reducing inflammation, regulating endothelial tone, improving mitochondrial function, and reducing oxidative stress. sEH inhibitor-10 has good research potential in metabolic, renal and cardiovascular diseases.
|
-
- HY-19504
-
-
- HY-121765
-
|
Dacisteine
N,S-Diacetyl-L-cysteine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM. Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation.
|
-
- HY-17408
-
-
- HY-19321
-
-
- HY-131728
-
-
- HY-U00386
-
-
- HY-10664
-
-
- HY-N5078
-
-
- HY-P1064
-
|
Apelin-36(human)
|
HIV
|
Infection
Metabolic Disease
Cardiovascular Disease
|
|
Apelin-36(human) is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC50=8.61). Apelin-36 has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
|
-
- HY-W021162
-
-
- HY-P1064A
-
|
Apelin-36(human) TFA
|
HIV
|
Infection
Metabolic Disease
Cardiovascular Disease
|
|
Apelin-36(human) TFA is an endogenous orphan G protein-coupled receptor APJ agonist, with an EC50 of 20 nM. Apelin-36(human) TFA shows high affinity to human APJ receptors expressed in HEK 293 cells (pIC550=8.61). Apelin-36(human) TFA has been linked to two major types of biological activities: cardiovascular and metabolic. Apelin-36(human) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
|
-
- HY-103462
-
|
TC-F2
|
FAAH
|
Cancer
Inflammation/Immunology
Metabolic Disease
|
|
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders.
|
-
- HY-U00191
-
-
- HY-107337S
-
-
- HY-103372
-
-
- HY-122537A
-
|
Arotinolol
|
Adrenergic Receptor
5-HT Receptor
|
Cardiovascular Disease
|
|
Arotinolol is a nonselective α/β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. Arotinolol is an antihypertensive agent for the treatment of a variety of cardiovascular pathologies as well as non-cardiovascular diseases.
|
-
- HY-70037
-
-
- HY-105697
-
|
Protoveratrine A
NSC 7526; Protalba; Protoveratrin
|
Others
|
Cardiovascular Disease
|
|
Protoveratrine A (NSC 7526; Protalba; Protoveratrin) is an alkaloid with strong cardiostimulant and vasoconstrictive effects, which can be used in the study of hypertension and other cardiovascular diseases.
|
-
- HY-N4305
-
-
- HY-70037A
-
-
- HY-N1913
-
-
- HY-70037S
-
-
- HY-N6881
-
|
Gypenoside XIII
|
Others
|
Cardiovascular Disease
|
|
Gypenoside XIII is belonging to the gypenosides. Gypenosides, extracted from Gynostemma pentaphyllum, have various pharmacological properties and protect against cardiovascular diseases, especially atherosclerosis.
|
-
- HY-136576
-
|
RP101075
|
LPL Receptor
Drug Metabolite
|
Inflammation/Immunology
|
|
RP101075, an active metabolite of Ozanimod, is a potent, orally active S1PR (sphingosine-1-phosphate receptor 1) agonist, with an EC50 of 0.27 nM. RP101075 displays >100-fold selectivity over S1PR5 (EC50=5.9 nM) and >10000-fold over S1PR 2, 3, and 4. RP101075 displays superior cardiovascular safety profile.
|
-
- HY-109136
-
|
Runcaciguat
BAY 1101042
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
Runcaciguat is an orally active stimulator of soluble guanylate cyclase, and is used in the research of cardiovascular and renal diseases combined with selective partial adenosine A1 receptor agonists.
|
-
- HY-70037AS
-
-
- HY-145197
-
-
- HY-N1362
-
|
Salvianolic acid B
Lithospermic acid B
|
Autophagy
|
Cardiovascular Disease
|
|
Salvianolic acid B is an active ingredient of Salvia miltiorrhiza, which has been widely applied in China for the management of various microcirculation-related disorders, such as cardiovascular disease, cerebrovascular disease, and diabetic vascular complication.
|
-
- HY-N1370
-
-
- HY-N0360
-
|
Dihydrotanshinone I
|
SARS-CoV
|
Cardiovascular Disease
|
|
Dihydrotanshinone I is a natural compound extracted from Salvia miltiorrhiza Bunge which has been widely used for treating cardiovascular diseases. Dihydrotanshinone I exhibits entry-blocking effect for MERS-CoV.
|
-
- HY-N4271
-
|
Protogracillin
|
Others
|
Cardiovascular Disease
|
|
Protogracillin is a steroidal saponin isolated from Dioscorea zingiberensis Wright (DZW). Steroidal saponins from DZW rhizomes have the potential to reduce the risk of cardiovascular diseases by anti-thrombotic action.
|
-
- HY-119727
-
-
- HY-137431A
-
|
(R)-Asundexian
(R)-BAY-2433334
|
Others
|
Cardiovascular Disease
|
|
(R)-Asundexian ((R)-BAY-2433334) is the enantiomer of Asundexian (HY-137431). (R)-Asundexian can be used in studies of cardiovascular disease (especially thrombotic or thromboembolic disease), edema, and ophthalmic disease.
|
-
- HY-106950
-
|
Fosfructose
Diphosphofructose; Esafosfan; FDP
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Fosfructose (Diphosphofructose;Esafosfan;FDP) is a cytoprotective natural sugar phosphate for the potential treatment of cardiovascular ischemia, sickle cell anemia and asthma. It acts by stimulating anaerobic glycolysis which generates adenosine triphosphate under ischemic conditions.
|
-
- HY-151094
-
|
FTEAA
|
Monoamine Oxidase
|
Neurological Disease
|
|
FTEAA is a 4-styrylpiperidine inhibitor. FTEAA exhibits potent inhibitory effect towards both monoamine oxidase with IC50s of 0.52 μM (MAO-A), 1.02 μM (MAO-B), respectively. MAO inhibitors can be used for cardiovascular, neurological and oncological disorders research.
|
-
- HY-N2174
-
-
- HY-100795
-
|
Pirmenol
Cl-845 free base; (±)-Pirmenol
|
mAChR
Potassium Channel
|
Cardiovascular Disease
|
|
Pirmenol is an orally active antiarrhythmic agent. Pirmenol inhibits IK.ACh (IC50: 0.1 μM) by blocking mAchR. Pirmenol can be used in the research of cardiovascular disease, such as atrial fibrillation.
|
-
- HY-146019
-
|
HIV-1 inhibitor-24
|
HIV
|
Infection
|
|
HIV-1 inhibitor-24 (compound S-12a) is a highly potent HIV-1 reverse transcriptase, with an IC50 value of 9.5 nM. HIV-1 inhibitor-24 has high antiretroviral activity against WT HIV-1 with an EC50 of 1.6 nM, and exhibits relatively low cytotoxicity with a CC50 of 9.07 μM in MT-4 cells. HIV-1 inhibitor-24 is well tolerated at a dose of 2 g/kg in mice and has a significant cardiovascular safety.
|
-
- HY-153491
-
|
Olezarsen
ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx
|
Others
|
Cardiovascular Disease
|
|
Olezarsen is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
|
-
- HY-100795A
-
|
Pirmenol hydrochloride
(±)-Pirmenol hydrochlorid
|
mAChR
Potassium Channel
|
Cardiovascular Disease
|
|
Pirmenol ((±)-Pirmenol) hydrochloride is an orally active antiarrhythmic agent. Pirmenol hydrochloride inhibits IK.ACh (IC50: 0.1 μM) by blocking mAchR. Pirmenol hydrochloride can be used in the research of cardiovascular disease, such as atrial fibrillation.
|
-
- HY-153491A
-
|
Olezarsen sodium
ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium
|
Others
|
Cardiovascular Disease
|
|
Olezarsen sodium is an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.
|
-
- HY-12124
-
|
BBS-4
|
NO Synthase
|
Cardiovascular Disease
|
|
BBS-4 is a potent and selective inducible nitric oxide synthase (NOS2) dimerization inhibitor, with an IC50 of 0.49 nM. BBS-4 can protect mice from the cardiovascular dysfunction of sepsis.
|
-
- HY-147292
-
-
- HY-106950A
-
|
Fosfructose trisodium
Diphosphofructose trisodium; Esafosfan trisodium; FDP trisodium
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Fosfructose trisodium (Diphosphofructose trisodium;Esafosfan trisodium;FDP trisodium) is a cytoprotective natural sugar phosphate for the potential treatment of cardiovascular ischemia, sickle cell anemia and asthma. It acts by stimulating anaerobic glycolysis which generates adenosine triphosphate under ischemic conditions.
|
-
- HY-115876
-
-
- HY-125791
-
-
- HY-114683
-
|
KS370G
|
Others
|
Cardiovascular Disease
|
|
KS370G is an orally active hypoglycemic and cardiovascular protective agent. KS370G improves left ventricular hypertrophy and function in pressure-overload mice heart. KS370G reduces renal obstructive nephropathy.
|
-
- HY-N7513
-
|
Homovanillyl alcohol
|
Drug Metabolite
|
Cardiovascular Disease
|
|
Homovanillyl alcohol is a biological metabolite of Hydroxytyrosol. Hydroxytyrosol is a phenolic compound that is present in virgin olive oil (VOO) and wine. Homovanillyl alcohol protects red blood cells (RBCs) from oxidative injury and has protective effect on cardiovascular disease.
|
-
- HY-N0738
-
-
- HY-B1735
-
|
Picotamide
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases.
|
-
- HY-17503S
-
-
- HY-142932
-
|
BTK-IN-6
|
Btk
|
Cancer
Inflammation/Immunology
Neurological Disease
|
|
BTK-IN-6 is a potent inhibitor of Bruton's Tyrosine Kinase (BTK). BTK is a member of the Tec family of tyrosine kinases and plays an important role in the regulation of early B-cell development and mature B-cell activation and survival. BTK-IN-6 has the potential for the research of immune disorders, cancer, cardiovascular diseases, viral infections, inflammation, metabolism/endocrine function disorders, and neurological disorders (extracted from patent WO2021136219A1, compound 8).
|
-
- HY-142050
-
|
(R)-IDHP
|
Calcium Channel
|
Cardiovascular Disease
|
|
(R)-IDHP is an isomer of IDHP, a salvia metabolite that exerts vasorelaxant effects by inhibiting Ca 2+ release and Ca 2+ inward flow in voltage-dependent and receptor-operated calcium channels in vascular smooth muscle cells. IDHP is used in studies of cardiovascular disease.
|
-
- HY-17503S2
-
-
- HY-17503S1
-
-
- HY-17464S
-
-
- HY-17464S1
-
-
- HY-113289
-
|
Brassicasterol
|
Androgen Receptor
HSV
Bacterial
Drug Metabolite
|
Cancer
Infection
|
|
Brassicasterol, a metabolite of Ergosterol, plays a role in the inhibitory effect on bladder carcinogenesis promotion via androgen signaling. Brassicasterol shows dual anti-infective properties against HSV-1 (IC50=1.2 µM) and Mycobacterium tuberculosis, and cardiovascular protective effect. Brassicasterol exerts an anti-cancer effect by dual-targeting AKT and androgen receptor signaling in prostate cancer.
|
-
- HY-141511
-
|
Coppersensor 1
|
Fluorescent Dye
|
Cancer
Neurological Disease
|
|
Coppersensor-1 (CS1) is a membrane-permeable fluorescent dye. Coppersensor-1 has a picomolar affinity for Cu + with high selectivity over competing cellular metalions. Coppersensor-1 as a probe, can selective and sensitive detection of copper(I) ions (Cu +) in biological samples, including live cells. Coppersensor-1 can be used for the research of imaging of severe diseases such as cancer, cardiovascular disorders and neurogenerative diseases. Storage: protect from light.
|
-
- HY-N0534
-
|
Vitexin-2"-O-rhamnoside
|
Others
|
Cardiovascular Disease
|
|
Vitexin-2"-O-rhamnoside, a main flavonoid glycoside of the leaves of Cratagus pinnatifida Bge, contributes to the protection against H2O2-mediated oxidative stress damage and has potential to treat cardiovascular system diseases.
|
-
- HY-69019
-
-
- HY-126293
-
|
Apelin agonist 1
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
Apelin agonist 1 is an oral selective apelin agonist AM-2995, a agonist of the APJ (APLNR, angiotensin receptor like-1) receptor, may be used in the treatment of cardiovascular conditions. Apelin agonist 1 is extracted from patent WO 2018097944 (210.0), Example 210.0.
|
-
- HY-152899
-
|
Selachyl alcohol
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Selachyl alcohol is an orally active antihypertensive agent. Selachyl alcohol has similar activities with antihypertensive neutral renomedullary lipid (ANRL). Selachyl alcohol is an alkylglycerol compound in shark liver oil mixture with properties that reduce lung metastasis. Selachyl alcohol can be used for cardiovascular disease research.
|
-
- HY-148187
-
-
- HY-148795
-
-
- HY-P1131A
-
|
M617 TFA
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
|
|
M617 TFA is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617 TFA, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.
|
-
- HY-P1131
-
|
M617
|
Neuropeptide Y Receptor
|
Cardiovascular Disease
|
|
M617 is a selective galanin receptor 1 (GAL1) agonist, with Kis of 0.23 and 5.71 nM for GAL1 and GAL2, respectively. M617, acting through its central GAL1, can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.
|
-
- HY-N6256
-
-
- HY-N0540
-
|
Cynaroside
Luteolin 7-glucoside; Luteolin 7-O-β-D-glucoside
|
Influenza Virus
DNA/RNA Synthesis
Apoptosis
Parasite
Bacterial
Fungal
|
Cancer
Infection
|
|
Cynaroside (Luteolin 7-glucoside) is a flavonoid compound that exhibits anti-oxidative capabilities. Cynaroside is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC50 of 32 nM. Cynaroside also is a promising inhibitor for H2O2-induced apoptosis, has cytoprotection against oxidative stress-induced cardiovascular diseases. Cynaroside also has antibacterial, antifungal and anticancer activities, antioxidant and anti-inflammatory activities.
|
-
- HY-129459
-
-
- HY-P2491
-
-
- HY-143314
-
-
- HY-150963
-
|
Renin inhibitor-1
|
Renin
|
Cardiovascular Disease
|
|
Renin inhibitor-1 (compound 26) is a potent and orally active renin inhibitor with IC50s of 0.9, 1.8 nM for rh-renin and hPRA, respectively. Renin inhibitor-1 shows antihypertensive efficacy. Renin inhibitor-1 has the potential for the research of hypertension and cardiovascular/renal diseases.
|
-
- HY-P99696
-
-
- HY-119873
-
|
Celiprolol
REV 5320
|
NO Synthase
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure.
|
-
- HY-B1264
-
|
Celiprolol hydrochloride
|
NO Synthase
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure.
|
-
- HY-148322
-
|
Sirtuin modulator 5
|
Sirtuin
|
Cancer
Infection
Metabolic Disease
Inflammation/Immunology
Neurological Disease
|
|
Sirtuin modulator 5 is a sirtuin modulating agent. Sirtuin modulator 5 can activate SIRT1 with a DC50 value of <50 μM. Sirtuin modulator 5 can be used for increasing the lifespan of a cell and used for the research of variety of diseases including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity.
|
-
- HY-151350
-
-
- HY-W011690
-
-
- HY-U00397
-
-
- HY-121383
-
-
- HY-N3307
-
-
- HY-N10047
-
|
7,8-Didehydrocimigenol
|
NF-κB
PPAR
|
Cardiovascular Disease
|
|
7,8-Didehydrocimigenol is an active triterpenoid that can be isolated from Cimicifugae rhizoma. 7,8-Didehydrocimigenol inhibits TNF-α-induced VCAM-1 expression, inhibits NF-kB activity and phosphorylation of ERK1/2 and Akt, increases PPAR-γ expression. 7,8-Didehydrocimigenol can be used for the research of cardiovascular disorders such as atherosclerosis.
|
-
- HY-122778
-
|
δ-Tocotrienol
|
Others
|
Cancer
Neurological Disease
Cardiovascular Disease
|
|
δ-Tocotrienol is a Vitamin E in vegetables, fruits, seeds, nuts, grains and oils. Vitamin E has become well known for its role as an antioxidant, in lowering cholesterol and other lipids, as a neuroprotective and anticancer agent, and in cardiovascular disease protection.
|
-
- HY-B1416A
-
-
- HY-103080
-
|
CMF019
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
CMF019 is a potent and small molecule agonist at Apelin receptor (APJ) with G protein bias. CMF019 binds to APJ with pKi values of 8.58, 8.49 and 8.71 for human, rat, and mouse, respectively. CMF019 mimics the beneficial cardiovascular actions of apelin in rodents. Apelin receptor (APJ) is a G protein-coupled receptor (GPCR) activated by the endogenous peptide apelin.
|
-
- HY-N6979
-
|
Crustecdysone
20-Hydroxyecdysone
|
Caspase
Autophagy
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Crustecdysone (20-Hydroxyecdysone) is a naturally occurring ecdysteroid hormone isolated from Serratula coronata which controls the ecdysis (moulting) and metamorphosis of arthropods, it inhibits caspase activity and induces autophagy via the 20E nuclear receptor complex, EcR-USP. Crustecdysone exhibits regulatory or protective roles in the cardiovascular system. Crustecdysone is an active metabolite of Ecdysone (HY-N0179).
|
-
- HY-P1548
-
-
- HY-P1548B
-
-
- HY-P1548A
-
-
- HY-B1334
-
|
Perhexiline
|
Mitochondrial Metabolism
Apoptosis
|
Cancer
Cardiovascular Disease
|
|
Perhexiline is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline can be used in the research of cancers, and cardiovascular disease like angina.
|
-
- HY-B1334A
-
|
Perhexiline maleate
|
Mitochondrial Metabolism
Apoptosis
|
Cancer
Cardiovascular Disease
|
|
Perhexiline maleate is an orally active CPT1 and CPT2 inhibitor that reduces fatty acid metabolism. Perhexiline maleate induces mitochondrial dysfunction and apoptosis in hepatic cells. Perhexiline maleate can cross the blood brain barrier (BBB) and shows anti-tumor activity. Perhexiline maleate can be used in the research of cancers, and cardiovascular disease like angina.
|
-
- HY-112233
-
|
O-304
|
AMPK
|
Metabolic Disease
Cardiovascular Disease
|
|
O-304 is a first-in-class, orally available pan-AMPK activator, which increases AMPK activity by suppressing the dephosphorylation of pAMPK. O-304 exhibits a great potential as a agent to treat type 2 diabetes (T2D) and associated cardiovascular complications .
|
-
- HY-34350
-
|
2-(Aminomethyl)phenol
2-Hydroxybenzylamine; o-Hydroxybenzylamine; 2-HOBA
|
Reactive Oxygen Species
|
Inflammation/Immunology
Cardiovascular Disease
|
|
2-(Aminomethyl)phenol (2-Hydroxybenzylamine), a selective dicarbonyl scavenger, is an antioxidant and scavanger of free radicals and isolevuglandins (IsoLGs). 2-(Aminomethyl)phenol can be used in the research of inflammation and cardiovascular disease, such as atherosclerosis, early recurrence of atrial fibrillation (AF) and arrhythmias.
|
-
- HY-142619
-
|
TP0586352
|
Bacterial
|
Infection
|
|
TP0586352 is a LpxC inhibitor that is effective against carbapenem-resistant Klebsiella pneumoniae and does not pose a cardiovascular risk.
|
-
- HY-143315
-
-
- HY-143220
-
-
- HY-125976
-
-
- HY-118643
-
|
Cimlanod
BMS-986231; CXL-1427
|
Others
|
Cardiovascular Disease
|
|
Cimlanod (BMS-986231) is a second-generation Nitroxyl (HNO) donor for heart failure. Cimlanod (BMS-986231) delivers HNO via pH-dependent chemical breakdown when exposed to the neutral pH environment of the bloodstream. Cimlanod (BMS-986231) possesses positive lusitropic and inotropic as well as vasodilatory effects.
|
-
- HY-N0418
-
-
- HY-N0712
-
|
Typhaneoside
|
Autophagy
|
Inflammation/Immunology
Cardiovascular Disease
|
|
Typhaneoside, extracted from Typha angustifolia L., Typhaneoside can inhibit the excessive autophagy of hypoxia/reoxygenation cells and increase the phosphorylation of Akt and mTOR. Typhaneoside has certain effects on the cardiovascular system, including lowering blood lipid levels, promoting antiatherosclerosis activities, as well as improving immune and coagulation function.
|
-
- HY-139572
-
-
- HY-126548
-
-
- HY-125851
-
|
TP-008
|
TGF-β Receptor
|
Inflammation/Immunology
|
|
TP-008 is a potent, selective and orally active (Activin-Like Kinase 5) ALK5 inhibitor with pIC50 and pEC50 values of 7.6 and 6.63, respectively. TGFβRI-IN-2 can produce observed cardiac toxicity in vivo at high dose.
|
-
- HY-N1356
-
-
- HY-16910G
-
|
WIKI4
|
Wnt
|
Cancer
Cardiovascular Disease
|
|
WIKI4 (GMP) is WIKI4 (HY-16910) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. WIKI4 is a potent tankyrase inhibitor.
|
-
- HY-123825
-
-
- HY-151123
-
|
Pelacarsen
AKCEA-APO(a)-LRx; TQJ230
|
Others
|
Cardiovascular Disease
|
|
Pelacarsen (AKCEA-APO(a)-LRx) is a liver-specific antisense oligonucleotide against apolipoprotein(a) that reduces lipoprotein(a) up to 80% with good tolerability.
|
-
- HY-108611
-
|
AACOCF3
Arachidonyl trifluoromethyl ketone
|
Phospholipase
|
Cardiovascular Disease
|
|
AACOCF3 (Arachidonyl trifluoromethyl ketone) is a cell-permeant trifluoromethyl ketone analog of arachidonic acid. AACOCF3 is a potent and selective slow binding inhibitor of the 85-kDa cytosolic phospholipase A2 (cPLA2). AACOCF3 blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. AACOCF3 inhibits glucose-induced insulin secretion from isolated rat islets. AACOCF3 has the potential for the research of cardiovascular disease.
|
-
- HY-121955
-
-
- HY-N6934
-
-
- HY-108801
-
|
Aflibercept
VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1
|
VEGFR
|
Metabolic Disease
Cardiovascular Disease
|
|
Aflibercept (VEGF Trap) is a soluble decoy VEGFR constructed by fusing the Ig domains of VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease.
|
-
- HY-N0655
-
-
- HY-P3977
-
|
ACTH (3-24) (human, bovine, mouse, ovine, porcine, rabbit, rat)
|
Melanocortin Receptor
|
Cancer
Inflammation/Immunology
Cardiovascular Disease
|
|
ACTH (3-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) is the 3-24 fragment of adrenocorticotropic hormone (ACTH). ACTH (3-24) (human, bovine, mouse, ovine, porcine, rabbit, rat) can be used for research of a variety of diseases, including cancer, immune diseases, cardiovascular disease.
|
-
- HY-115688
-
-
- HY-N0728S
-
|
α-Linolenic acid-d5
|
PI3K
Akt
|
Cancer
Cardiovascular Disease
|
|
α-Linolenic acid-d5 is the deuterium labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer[1].
|
-
- HY-N0728S3
-
|
α-Linolenic acid-13C18
|
PI3K
Akt
|
Cancer
Cardiovascular Disease
|
|
α-Linolenic acid- 13C18 is the 13C labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer[1].
|
-
- HY-N0728S2
-
|
α-Linolenic acid-d14
|
PI3K
Akt
|
Cancer
Cardiovascular Disease
|
|
α-Linolenic acid-d14 is the deuterium labeled α-Linolenic acid. α-Linolenic acid, isolated from seed oils, is an essential fatty acid that cannot be synthesized by humans. α-Linolenic acid can affect the process of thrombotic through the modulation of PI3K/Akt signaling. α-Linolenic acid possess the anti-arrhythmic properties and is related to cardiovascular disease and cancer[1].
|
-
- HY-N10597
-
|
5'''-O-Feruloyl complanatoside B
|
Others
|
Cancer
Metabolic Disease
Cardiovascular Disease
|
|
5'''-O-Feruloyl complanatoside B is isolated from Astragali Semen, the seeds of Astragalus Complanatus. Semen Astragali Complanati (SAC) include fatty acids, amino acids, polysaccharides, flavonoids, triterpene glycosides and trace elements; have been reported to involve in chronic diseases such as cardiovascular diseases, diabetes mellitus and cancers.
|
-
- HY-13527
-
|
LY310762
|
5-HT Receptor
|
Neurological Disease
Cardiovascular Disease
|
|
LY310762 is a selective 5-HT1D receptor antagonist (Ki=249 nM) with a weak affinity for 5-HT1B receptor. LY310762 effectively abolishes the renal vasodilatory effects of 5-HTSumatriptan (HY-B0121B)-induced decrease in excitatory postsynaptic potential (EPSC) amplitude.
|
-
- HY-116169
-
-
- HY-N0714
-
|
Berbamine
|
NF-κB
Autophagy
|
Cancer
|
|
Berbamine is a natural compound extracted from traditional Chinese medicine Phellodendron amurense Rupr. with anti-tumor, immunomodulatory and cardiovascular effects. Berbamine is a calcium channel blocker.
|
-
- HY-14299
-
|
Indacaterol
|
Adrenergic Receptor
|
Inflammation/Immunology
Cardiovascular Disease
|
|
Indacaterol is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol can also be used in cardiovascular disease research.
|
-
- HY-145653
-
-
- HY-N2007
-
|
Veratric acid
3,4-Dimethoxybenzoic acid
|
COX
Reactive Oxygen Species
|
Inflammation/Immunology
Cardiovascular Disease
|
|
Veratric acid (3,4-Dimethoxybenzoic acid) is an orally active phenolic compound derived from vegetables and fruits, has antioxidant and anti-inflammatory activities. Veratric acid also acts as a protective agent against hypertension-associated cardiovascular remodelling. Veratric acid reduces upregulated COX-2 expression, and levels of PGE2, IL-6 after UVB irradiation.
|
-
- HY-N0799
-
|
Protodioscin
|
Endogenous Metabolite
|
Cancer
|
|
Protodioscin, a major steroidal saponin in Trigonella foenum-graecum Linn., has been shown to exhibit multiple biological actions, such as anti-hyperlipidemia, anti-cancer, sexual effects and cardiovascular properties.
|
-
- HY-17557
-
|
Calcium N5-methyltetrahydrofolate
NSC173328
|
Antifolate
|
Cancer
|
|
Calcium N5-methyltetrahydrofolate(NSC173328) is the calcium salt of levomefolic acid, which has been proposed for treatment of cardiovascular disease and advanced cancers such as breast and colorectal cancers.
|
-
- HY-15556A
-
-
- HY-15556
-
-
- HY-110112
-
|
BTT-3033
|
Integrin
Apoptosis
|
Cancer
Inflammation/Immunology
Cardiovascular Disease
|
|
BTT-3033 is an orally active conformation-selective inhibitor of α2β1 (EC50: 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen Ⅰ and cell proliferation, and induces cell apoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease.
|
-
- HY-W111226
-
|
Fmoc-His(3-Me)-OH
|
Amino Acid Derivatives
Amyloid-β
|
Cardiovascular Disease
|
|
Fmoc-His(3-Me)OH derives Histidine-associating compounds with biological activity. Fmoc-His(3-Me)OH, with Fmoc-citrulline-OH, Fmoc-His(1-Me)-OH together, forms tri-peptides and shows vasodilating effect with EC50s of 2.7-4.7 mM in 1.0 mM Phenylephrine (PE)-contracted aorta rings. Fmoc-His(3-Me)OH (resin) also makes Methyl-His-Gly-Lys (His(3-Me)-Gly-Lys), thus acts as an [Ca 2+]i inhibitor. Fmoc-His(3-Me)OH methylates NAHIS02, making it unable to block the Alzheimer's Aβ channel.
|
-
- HY-15306
-
|
Eltrombopag
SB-497115
|
Thrombopoietin Receptor
Bacterial
Apoptosis
|
Cancer
Infection
Cardiovascular Disease
|
|
Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well.
|
-
- HY-148837
-
|
c-Myc inhibitor 7
|
c-Myc
Casein Kinase
|
Cancer
Infection
Cardiovascular Disease
|
|
c-Myc inhibitor 7 is a c-Myc inhibitor and a multiple target protein degrader. c-Myc inhibitor 7 effective degrades c-MYC, CK1α, GSPT1 and IKZF1/2/3 proteins in a variety of tumor cells. c-Myc inhibitor 7 can be used for c-Myc high expression related disease research, such as cancer, cardiovascular and cerebrovascular diseases, and viral infection.
|
-
- HY-P1525
-
-
- HY-151972
-
-
- HY-15306A
-
|
Eltrombopag Olamine
Eltrombopag diethanolamine salt; SB-497115GR
|
Thrombopoietin Receptor
Bacterial
Apoptosis
|
Cancer
Infection
Cardiovascular Disease
|
|
Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well.
|
-
- HY-109523
-
|
Cerivastatin sodium
|
HMG-CoA Reductase (HMGCR)
Ferroptosis
|
Cancer
Cardiovascular Disease
|
|
Cerivastatin sodium is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin sodium reduces low-density lipoprotein cholesterol levels. Cerivastatin sodium also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect.
|
-
- HY-100434
-
|
PD-161570
|
FGFR
PDGFR
EGFR
Src
TGF-β Receptor
|
Cancer
Cardiovascular Disease
|
|
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC50s of 450 nM and 622 nM, respectively. PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor.
|
-
- HY-129458
-
|
Cerivastatin
|
HMG-CoA Reductase (HMGCR)
Ferroptosis
|
Cancer
Cardiovascular Disease
|
|
Cerivastatin is a synthetic lipid-lowering agent and a highly potent, well-tolerated and orally active HMG-CoA reductase inhibitor, with a Ki of 1.3 nM/L. Cerivastatin reduces low-density lipoprotein cholesterol levels. Cerivastatin also inhibits proliferation and invasiveness of MDA-MB-231 cells, mainly by RhoA inhibition, and has anti-cancer effect.
|
-
- HY-P1525A
-
-
- HY-148312
-
|
Sirtuin modulator 4
|
Sirtuin
|
Cancer
Inflammation/Immunology
Neurological Disease
Cardiovascular Disease
|
|
Sirtuin modulator 4 (compound 12) is a sirtuin modulator. Sirtuin modulator 4 shows inhibitory effect to SIRT1 with an EC50 value of 51-100 μM. Sirtuin modulator 4 may be used for the research of increasing the lifespan of a cell, and preventing a wide variety of diseases and disorders including, for example, diabetes, obesity, neurodegenerative diseases, cardiovascular diseases, inflammation and cancer.
|
-
- HY-150508
-
|
MK-0159
|
CD38
|
Metabolic Disease
Cardiovascular Disease
|
|
MK-0159 (compound 37) is an orally active, potent and selective CD38 inhibitor, with IC50 values of 22, 3, and 70 nM for human, mouse and rat CD38, respectively. MK-0159 also shows good microsomal stability for human and rodent liver microsomes. MK-0159 increases NAD + (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
|
-
- HY-N2007S
-
|
Veratric acid-d6
3,4-Dimethoxybenzoic acid-d6
|
COX
Reactive Oxygen Species
|
Inflammation/Immunology
Cardiovascular Disease
|
|
Veratric acid-d6 is deuterium labeled Veratric acid. Veratric acid (3,4-Dimethoxybenzoic acid) is an orally active phenolic compound derived from vegetables and fruits, has antioxidant[1] and anti-inflammatory activities[3]. Veratric acid also acts as a protective agent against hypertension-associated cardiovascular remodelling[2]. Veratric acid reduces upregulated COX-2 expression, and levels of PGE2, IL-6 after UVB irradiation[3].
|
-
- HY-13603
-
|
Crolibulin
EPC2407
|
Microtubule/Tubulin
Apoptosis
|
Cancer
|
|
Crolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicity.
|
-
- HY-B2163
-
|
Astaxanthin
|
PPAR
Reactive Oxygen Species
STAT
NF-κB
Apoptosis
|
Cancer
Metabolic Disease
Cardiovascular Disease
|
|
Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed.
|
-
- HY-118339
-
|
PF-4479745
|
5-HT Receptor
|
Cancer
|
|
PF-4479745 is a potent and selective 5-HT2C receptor agonist (EC50: 10 nM, ki: 15 nM). PF-4479745 can be used in the research of cardiovascular disease like hypertension.
|
-
- HY-P1065A
-
|
Apelin-36(rat, mouse) TFA
|
HIV
|
Infection
Metabolic Disease
Cardiovascular Disease
|
|
Apelin-36(rat, mouse) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-36(rat, mouse) TFA binds to APJ receptors with an IC50 of 5.4 nM, and potently inhibits cAMP production with an EC50 of 0.52 nM. Apelin-36(rat, mouse) TFA blocks entry of some HIV-1 and HIV-2 strains into NP-2/CD4 cells expressing APJ.
|
-
- HY-125911
-
|
Gossypin
|
NF-κB
|
Cancer
Inflammation/Immunology
Cardiovascular Disease
|
|
Gossypin is a flavone isolated from Hibiscus vitifolius and has antioxidant, antiinflammatory, anticancer, anticataract, antidiabetic, and hepatoprotective activities. Gossypin inhibits NF-κB and NF-κB-regulated gene expression. Gossypin inhibits RANKL-induced osteoclastogenesis both in mouse primary bone marrow cells and RAW 264.7 cells in vitro.
|
-
- HY-15306S
-
|
(E/Z)-Eltrombopag-13C4
(E/Z)-SB-497115-13C4
|
Thrombopoietin Receptor
Bacterial
Apoptosis
|
Cancer
Infection
Cardiovascular Disease
|
|
(E/Z)-Eltrombopag- 13C4 is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13C labeled. Z-Eltrombopag is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well[1][2][3][4][5].
|
-
- HY-W012977
-
-
- HY-B0378A
-
-
- HY-W011690S
-
|
L-Homocystine-d8
|
Endogenous Metabolite
|
|
|
L-Homocystine-d8 is the deuterium labeled L-Homocystine. L-Homocystine is the oxidized member of the L-homocysteine. Homocysteine is a pro-thrombotic factor, vasodilation impairing agent, pro-inflammatory factor and endoplasmatic reticulum-stress inducer used to study cardiovascular disease mechanisms.
|
-
- HY-N0515
-
|
Ophiopogonin D
|
PPAR
NF-κB
Calcium Channel
|
Inflammation/Immunology
Cardiovascular Disease
|
|
Ophiopogonin D, isolated from the tubers of Ophiopogon japonicus, is a rare naturally occurring C29 steroidal glycoside. Ophiopogonin D is a CYP2J3 inducer that significantly inhibits Ang II induced NF-κB nuclear translocation, IκBα down-regulation, intracellular Ca 2+ overload and activation of pro-inflammatory cytokines by increasing the expression of CYP2J2/EETs and PPARα in human umbilical vein endothelial cells (HUVECs). Ophiopogonin D has been used to treat inflammatory and cardiovascular diseases for thousands of years.
|
-
- HY-N0393
-
|
Glabridin
|
PPAR
Reactive Oxygen Species
Bacterial
|
Cancer
Infection
Inflammation/Immunology
|
|
Glabridin is a natural isoflavan from Glycyrrhiza uralensis, binds to and activates PPARγ, with an EC50 of 6115 nM. Glabridin exhibits antioxidant, anti-bacterial, anti-nephritic, anti-diabetic, anti-fungal, antitumor, anti-inflammatory, antiosteoporotic, cardiovascular protective, neuroprotective and radical scavenging activities.
|
-
- HY-16693
-
|
LDN-27219
|
Others
|
Others
|
|
LDN-27219 is a reversible, slow-binding inhibitor of TGase. LDN-27219 inhibits human TGase with an IC50 value of 0.6 μM. LDN-27219 effectively decreases blood pressure and induces vasodilation, it can be used for the research of cardiovascular disease.
|
-
- HY-115688A
-
|
(S)-TXNIP-IN-1
|
Others
|
Others
|
|
(S)-TXNIP-IN-1 is the less active S-enantiomer of TXNIP-IN-1 (HY-115688). TXNIP-IN-1 is a TXNIP-TRX complex inhibitor which can be used in the research of TXNIP-TRX complex associated metabolic disorder (diabetes), cardiovascular disease, or inflammatory disease
|
-
- HY-N1485
-
|
Cycloastragenol
Astramembrangenin; Cyclosieversigenin
|
Telomerase
|
Inflammation/Immunology
Neurological Disease
|
|
Cycloastragenol (Astramembrangenin), the active form of astragaloside IV, has anti-oxidant, anti-inflammatory, anti-aging, anti-apoptotic, and cardiovascular protective effects. Cycloastragenol is a potent telomerase activator and can lengthen telomeres. Cycloastragenol alleviates age-related bone loss and improves bone microstructure and biomechanical properties.
|
-
- HY-P2703
-
|
Peptide YY (pig)
|
Neuropeptide Y Receptor
|
Endocrinology
Metabolic Disease
|
|
Peptide YY (pig) is a 36 amino acid gastrointestinal peptide, can be isolated from porcine duodenum. Peptide YY (pig) decreases appetite and food-intake by activation of the Y2 receptor. Peptide YY (pig) is present mainly in pancreatic endocrine cells with effect on both intestinal motility and the cardiovascular system.
|
-
- HY-18260
-
|
Bisphenol A
|
Endogenous Metabolite
|
Endocrinology
|
|
Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders.
|
-
- HY-143223
-
|
AS(3n-2)-Inclisiran
|
Ser/Thr Protease
|
Others
|
|
AS(3n-2)-Inclisiran is the antisense of Inclisiran with 3 N random site after the 2 bp spacer. Inclisiran is a double-stranded small interfering RNA (siRNA) molecule that inhibits the transcription of PCSK-9.
|
-
- HY-13524
-
-
- HY-13524A
-
-
- HY-N7627
-
-
- HY-103211
-
|
L748337
|
Adrenergic Receptor
|
Cancer
Metabolic Disease
Cardiovascular Disease
|
|
L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over β1 and β2 receptors. The Ki values of L748337 for β3-, β2- and β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively. L748337 couples predominantly to Gi to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC50 value of 11.6. L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases.
|
-
- HY-147234
-
-
- HY-138944
-
-
- HY-B0351
-
|
Taurine
2-Aminoethanesulfonic acid
|
Autophagy
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
|
Taurine, a sulphur-containing amino acid and an organic osmolyte involved in cell volume regulation, provides a substrate for the formation of bile salts, and plays a role in the modulation of intracellular free calcium concentration. Taurine has the ability to activate autophagy in adipocytes.
|
-
- HY-P1066A
-
|
Apelin-17(human, bovine) TFA
|
HIV
|
Infection
|
|
Apelin-17(human, bovine) TFA is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-17(human, bovine) TFA binds to human APJ receptors expressed in HEK 293 cells (pIC50=9.02). Apelin-17(human, bovine) TFA inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
|
-
- HY-P1066
-
|
Apelin-17(human, bovine)
|
HIV
|
Infection
|
|
Apelin-17(human, bovine) is an endogenous orphan G protein-coupled receptor APJ agonist. Apelin-17(human, bovine) binds to human APJ receptors expressed in HEK 293 cells (pIC50=9.02). Apelin-17(human, bovine) inhibits the entry of some HIV-1 and HIV-2 into the NP2/CD4 cells expressing APJ.
|
-
- HY-18260S1
-
|
Bisphenol A-d6
|
Endogenous Metabolite
|
Endocrinology
|
|
Bisphenol A-d6 is the deuterium labeled Bisphenol A. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[1][2][3].
|
-
- HY-141645
-
|
IMM-H007
WS070117
|
AMPK
TGF-β Receptor
NF-κB
JNK
AP-1
|
Metabolic Disease
Inflammation/Immunology
Cardiovascular Disease
|
|
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and JNK/AP1 signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis.
|
-
- HY-117281
-
-
- HY-18260S
-
|
Bisphenol A-d16
|
Endogenous Metabolite
|
Endocrinology
|
|
Bisphenol A-d16 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].
|
-
- HY-14299A
-
|
Indacaterol maleate
QAB149
|
Adrenergic Receptor
|
Endocrinology
|
|
Indacaterol maleate (QAB149) is an orally active ultra-long-acting β2 adrenergic receptor (ADRB2) agonist. Indacaterol maleate inhibits NF-κB activity in a β-arrestin2-dependent manner, preventing further lung damage and improving lung function in COPD (chronic obstructive pulmonary disorder). Indacaterol maleate can also be used in cardiovascular disease research.
|
-
- HY-18260S4
-
|
Bisphenol A-d4
|
Endogenous Metabolite
|
Endocrinology
|
|
Bisphenol A-d4 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].
|
-
- HY-18260S5
-
|
Bisphenol A-d4-1
|
Endogenous Metabolite
|
Endocrinology
|
|
Bisphenol A-d4-1 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3].
|
-
- HY-18260S3
-
|
Bisphenol A-4d
|
Endogenous Metabolite
|
Endocrinology
|
|
Bisphenol A-d8 is the deuterium labeled Bisphenol A[1]. Bisphenol A is a phenolic, organic synthetic compound widely used in the production of polycarbonate plastics and epoxy resins. Bisphenol A is a reproductive, developmental, and systemic toxicant, often classified as an endocrine-disrupting compound (EDC). Bisphenol A is associated with many diseases, including cardiovascular diseases, respiratory diseases, diabetes, kidney diseases, obesity, and reproductivedisorders[2][3][4].
|
-
- HY-P1208
-
|
PG-931
|
Melanocortin Receptor
|
Inflammation/Immunology
|
|
PG-931, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC50=0.58 nM) agonist and is more selective than for the hMC3R (IC50=55 nM) or the hMC5R (IC50=2.4 nM). PG-931 can reverse haemorrhagic shock and prevent multiple organ damage in vivo.
|
-
- HY-P1208A
-
|
PG-931 TFA
|
Melanocortin Receptor
|
Inflammation/Immunology
|
|
PG-931 TFA, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC50=0.58 nM) agonist and is more selective than for the hMC3R (IC50=55 nM) or the hMC5R(IC50=2.4 nM). PG-931 TFA can reverse haemorrhagic shock and prevent multiple organ damage in vivo.
|
-
- HY-P0049A
-
|
Argipressin diacetate
Arg8-vasopressin diacetate; AVP diacetate; ADH
|
Apoptosis
Vasopressin Receptor
|
Neurological Disease
|
|
Argipressin (diacetate) (AVP (diacetate), also known as antidiuretic hormone (ADH)) is a 9 amino acid neuropeptide secreted by the posterior pituitary. Argipressin (diacetate) (AVP (diacetate)) can regulate the biological effects of fluid balance, osmolality and cardiovascular through three separate G-protein coupled receptors (GPCRs), namely Avpr1a (V1a), Avpr1b (V1b) and Avpr2 (V2). Argipressin (diacetate) (AVP (diacetate)) also have potentially important effects on centrally regulated metabolic processes.
|
-
- HY-B0143S4
-
|
Niacin-15N,13C3
|
Autophagy
Endogenous Metabolite
|
|
|
Niacin- 15N, 13C3 is the 13C and 15N labeled Niacin[1]. Niacin (Vitamin B3) is an orally active water-soluble B3 vitamin that is an essential nutrient for humans. Niacin (Vitamin B3) plays a key role in energy metabolism, cell signaling cascades regulating gene expression and apoptosis. Niacin (Vitamin B3) is also used in the study of cardiovascular diseases[2][3].
|
-
- HY-P0093
-
|
Sincalide
Cholecystokinin octapeptide; CCK-8; SQ19844
|
Cholecystokinin Receptor
Apoptosis
PI3K
Akt
|
Cancer
Infection
|
|
Sincalide (Cholecystokinin octapeptide, CCK‐8) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. CCK‐8 can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. CCK‐8 is a major bioactive segment of CCK that retains most of the biological activities of CCK.
|
-
- HY-139560
-
-
- HY-139561
-
-
- HY-P0093A
-
|
Sincalide ammonium
Cholecystokinin octapeptide ammonium; CCK-8 ammonium; SQ19844 ammonium
|
Cholecystokinin Receptor
Apoptosis
PI3K
Akt
|
Cancer
Infection
|
|
Sincalide ammonium (Cholecystokinin octapeptide ammonium, CCK-8 ammonium) is a rapid-acting amino acid polypeptide hormone analogue of cholecystokinin (CCK) for intravenous use in postevacuation cholecystography. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK. CCK‐8 can promote gallbladder contraction by injection and helps diagnose gallbladder and pancreas disorders. Sincalide ammonium can increase bile secretion, cause the gallbladder to contract and relax the sphincter of Oddi, resulting in bile drainage into the duodenum. Sincalide ammonium is a major bioactive segment of CCK that retains most of the biological activities of CCK.
|
-
- HY-B0653
-
|
Levobupivacaine
(S)-(-)-Bupivacaine
|
Sodium Channel
Ferroptosis
|
Cancer
Neurological Disease
|
|
Levobupivacaine ((S)-(-)-Bupivacaine) is a long-acting amide local anaesthetic. Levobupivacaine exerts anaesthetic and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
|
-
- HY-B0653A
-
|
Levobupivacaine hydrochloride
(S)-(-)-Bupivacaine monohydrochloride
|
Sodium Channel
Ferroptosis
|
Neurological Disease
Cancer
|
|
Levobupivacaine hydrochloride ((S)-(-)-Bupivacaine monohydrochloride) is a long-acting amide local anaesthetic. Levobupivacaine hydrochloride exerts anaesthetic and analgesic effects through reversible blockade of neuronal sodium channel. Levobupivacaine hydrochloride can inhibit impulse transmission and conduction in cardiovascular and other tissues, possessing certain cardiac and CNS toxicity. Levobupivacaine hydrochloride is metabolized by hepatic cytochrome P450 (CYP450) enzymes in vivo. Levobupivacaine hydrochloride can also induce ferroptosis by miR-489-3p/SLC7A11 signaling in gastric cancer.
|
-
- HY-19762
-
-
- HY-120802
-
|
Navafenterol
AZD-8871; LAS191351
|
mAChR
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Navafenterol (AZD-8871) is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3 receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile.
|
-
- HY-120802A
-
|
Navafenterol saccharinate
AZD-8871 saccharinate; LAS191351 saccharinate
|
mAChR
Adrenergic Receptor
|
Infection
Inflammation/Immunology
|
|
Navafenterol (AZD-8871) saccharinate is an inhaled dual-acting, potent, selective, and long-lasting M3-antagonist/β2-agonist (MABA) with long-lasting effects and favorable safety profile. The pIC50 is 9.5 for human M3 receptor, and the pEC50 is 9.5 for β2-adrenoceptor. Navafenterol saccharinate can be used for the research of chronic obstructive pulmonary disease (COPD). Bronchoprotective and antisialagogue effects. Favorable cardiovascular profile.
|
-
- HY-15398
-
-
- HY-75958
-
|
Vitamin D4
22-Dihydroergocalciferol
|
VD/VDR
|
Metabolic Disease
|
|
Vitamin D4 (22-Dihydroergocalciferol) is a Vitamin D derived from fungi. The precursor of Vitamin D4 is 22,23-dihydroergosterol.
|
-
- HY-142778
-
|
Lp-PLA2-IN-10
|
Phospholipase
|
Metabolic Disease
Neurological Disease
|
|
Lp-PLA2-IN-10 is a potent inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2). Lp-PLA2 previously known as platelet- activating factor acetylhydrolase (PAF-AH), is a phospholipase A2 enzyme involved in hydrolysis of lipoprotein lipids or phospholipids. Lp-PLA2-IN-10 has the potential for the research of neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis (extracted from patent WO2022001881A1, compound 4).
|
-
- HY-14728
-
|
Aleglitazar
R1439; RO0728804
|
PPAR
|
Metabolic Disease
|
|
Aleglitazar (R1439) is a potent dual PPARα/γ agonist, with IC50s of 38 nM and 19 nM for human PPARa and PPARγ, respectively. Aleglitazar can be used for the research of type II diabetes.
|
-
- HY-N6626
-
-
- HY-150021
-
-
- HY-Q49697
-
-
- HY-16677A
-
|
Mofegiline hydrochloride
MDL72974A
|
Monoamine Oxidase
|
Neurological Disease
|
|
Mofegiline hydrochloride (MDL72974A) is an orally active and selective enzyme-activated irreversible inhibitor of MAO-B, with marked selectivity on the MAO-B over MAO-A with IC50s of 3.6 nM (MAO-B) and 680 nM (MAO-A), respectively. Mofegiline hydrochloride is also an inhibitor of semicarbazide-sensitive amine oxidase (SSAO).
|
-
- HY-P1106
-
|
K41498
|
CRFR
|
Cardiovascular Disease
|
|
K41498 is a potent and highly selective CRF2 receptor antagonist with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF2α, CRF2β and CRF1 receptors respectively. K41498 is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF2α- and hCRF2β-expressing cells. K41498 can be used for hypotension study.
|
-
- HY-N5004
-
-
- HY-B0428
-
|
Ozagrel
OKY-046
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Ozagrel (OKY-046)is an anti-asthmatic agent and a thromboxane A2 (TXA2) synthase inhibitor. Ozagrel is an antiplatelet agent, which selectively inhibits human platelet aggregation with an IC50 of 53.12 μM.
|
-
- HY-135883
-
-
- HY-P3108
-
-
- HY-A0182A
-
-
- HY-123983
-
|
HS56
|
Pim
DAPK
|
Cardiovascular Disease
|
|
HS56 is an ATP-competitive dual Pim/DAPK3 inhibitor with Ki values of 0.26, 0.208, 2.94, and ＞100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively. HS56 inhibits LC20 phosphorylation and smooth muscle contraction. HS56 decreases blood pressure in spontaneously hypertensive mice. HS56 can be used in research of hypertension.
|
-
- HY-15124
-
-
- HY-17436S1
-
|
Clevidipine-d7
|
Calcium Channel
|
Cardiovascular Disease
|
|
Clevidipine-d7 is the deuterium labeled Clevidipine. Clevidipine is a short-acting dihydropyridine calcium channel antagonist (IC50= 7.1 nM, V(H) = -40 mV ) under development for treatment of perioperative hypertension[1][2].
|
-
- HY-A0117
-
|
Temocaprilat
Temocapril diacid; Temocaprilate; RS 5139
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Temocaprilat (Temocapril diacid) is an inhibitor of angiotensin-converting enzyme (ACE). Temocaprilat alleviates the inhibitory effect of high glucose on the proliferation of aortic endothelial cells. Temocaprilat has potential applications in hypertension and vascular inflammation.
|
-
- HY-139465
-
|
Aficamten
CK-274; CK-3773274
|
Myosin
|
Cardiovascular Disease
|
|
Aficamten (CK-274) is a potent cardiac myosin inhibitor with an IC50 of 1.4 μM. Aficamten can be used for the research of hypertrophic cardiomyopathy (HCM).
|
-
- HY-114524
-
|
(E)-4-Oxo-2-nonenal
4-ONE
|
TRP Channel
|
Cardiovascular Disease
|
|
(E)-4-Oxo-2-nonenal (4-ONE) is one of the major hemolytic decomposition products of lipid hydroperoxides. (E)-4-Oxo-2-nonenal is a major product of the FeII-mediated breakdown of lipid hydroperoxides. (E)-4-Oxo-2-nonenal is a potent transient receptor potential ankyrin 1 (TRPA1) agonist.
|
-
- HY-113121S1
-
|
Vanillylmandelic acid-d1
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Vanillylmandelic acid-d is the deuterium labeled Vanillylmandelic acid. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM[1].
|
-
- HY-139876
-
-
- HY-139665
-
|
VB124
|
Monocarboxylate Transporter
|
Cardiovascular Disease
|
|
VB124 is an orally active, potent, and selective MCT4 inhibitor. VB124 can specifically inhibit lactate efflux with IC50s of 8.6 nM and 19 nM for lactate import and export in MDA-MB-231 cells, respectively. VB124 is highly selective for MCT4 over MCT1. VB124 can be used for the research of cardiac hypertrophy, heart failure, and metabolism.
|
-
- HY-W013812S2
-
|
Ethyl linoleate-d2
Linoleic Acid ethyl ester-d2; Mandenol-d2
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
Ethyl linoleate-d2 (Linoleic Acid ethyl ester-d2; Mandenol-d2) is the deuterium labeled Ethyl linoleate (HY-W013812). Ethyl linoleate (Linoleic Acid ethyl ester) inhibit the development of atherosclerotic lesions and the expression of inflammatory mediators.
|
-
- HY-N5006
-
-
- HY-100380
-
-
- HY-111372A
-
|
(Rac)-Finerenone
(Rac)-BAY 94-8862
|
Mineralocorticoid Receptor
|
Cardiovascular Disease
|
|
(Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold).
|
-
- HY-N4081
-
-
- HY-133149
-
-
- HY-114424A
-
-
- HY-B0341S
-
|
Nicorandil-d4
|
Potassium Channel
|
Cardiovascular Disease
|
|
Nicorandil-d4 (SG-75-d4) is the deuterium labeled Nicorandil. Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K+ channels and cardiac ATP-sensitive K+ channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases[1][2][3].
|
-
- HY-13422A
-
|
Zatebradine
UL-FS-49 free base; UL-FS-49CL free base
|
HCN Channel
|
Cardiovascular Disease
|
|
Zatebradine (UL-FS-49 (free base); UL-FS-49CL (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 value of 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively.
|
-
- HY-113301
-
-
- HY-N1798
-
-
- HY-124527
-
|
HET0016
|
Cytochrome P450
|
Cardiovascular Disease
|
|
HET0016 is a potent and selective 20-hydroxyeicosatetraenoic acid (20-HETE) synthase inhibitor, with IC50 values of 17.7 nM, 12.1 nM and 20.6 nM for recombinant CYP4A1-, CYP4A2- and CYP4A3-catalyzed 20-HETE synthesis, respectively. HET0016 also is a selective CYP450 inhibitor, which has been shown to inhibit angiogenesis and tumor growth.
|
-
- HY-B0612AS
-
|
Lercanidipine-13C,d3 hydrochloride
|
Calcium Channel
|
Cardiovascular Disease
|
|
Lercanidipine- 13C,d3 (hydrochloride) is the deuterium and 13C labeled Lercanidipine hydrochloride[1]. Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect[2][3][4].
|
-
- HY-18990
-
|
GSK180736A
|
ROCK
|
Cardiovascular Disease
|
|
GSK180736A is potent Rho-associated coiled-coil kinase 1 (ROCK1) inhibitor with an IC50 of 100 nM. GSK180736A is also a selective and ATP-competitive G protein-coupled receptor kinase 2 (GRK2) inhibitor with an IC50 of 0.77 μM.
|
-
- HY-N8144
-
|
Niga-ichigoside F1
|
Others
|
Cardiovascular Disease
|
|
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis.
|
-
- HY-P3878
-
-
- HY-18071A
-
|
BI-9627 hydrochloride
|
Na+/H+ Exchanger (NHE)
|
Cardiovascular Disease
|
|
BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury.
|
-
- HY-118824A
-
|
N-Feruloylserotonin
(E/Z)-Moschamine
|
Others
|
Cardiovascular Disease
|
|
N-Feruloylserotonin, an antioxidative component and bioactive serotonin derivative, from the Seed of Carthamus tinctorius L., ameliorates atherosclerosis and distensibility of the aortic wall in Kurosawa and Kusanagi-hypercholesterolemic (KHC) rabbits.
|
-
- HY-125772
-
|
Acetyl podocarpic acid anhydride
Acetylpodocarpic dimer; APD
|
LXR
|
Cardiovascular Disease
|
|
Acetyl podocarpic acid anhydride is a potent, semisynthetic liver X receptor(LXR) agonist derived from extracts of the mayapple. Acetyl podocarpic acid anhydride has the potential to be useful for the prevention and research of atherosclerosis, especially in the context of low HDL levels.
|
-
- HY-135151
-
|
Difluoro atorvastatin
Fluoroatorvastatin
|
Drug Metabolite
|
Cardiovascular Disease
|
|
Difluoro atorvastatin (Fluoroatorvastatin) is an impurity of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
|
-
- HY-139134
-
-
- HY-117006
-
|
E1231
1-{4-[2-(5-Methylfuran-2-yl)quinoline-4-carbonyl]piperazin-1-yl}ethan-1-one
|
Sirtuin
|
Cardiovascular Disease
|
|
E1231 is an orally active activator of Sirtuin 1 (SIRT1) (EC50=0.83 μM), to modulate cholesterol and lipid metabolism. E1231 interactes with SIRT1 (KD=9.61 μM) and deacetylated liver X receptor-alpha (LXRα), and increases ATP-binding cassette transporter A1 (ABCA1) expression. E1231 also reduces atherosclerotic plaque development in ApoE -/- mice model. E1231 can be used for research in cholesterol and lipid disorder-related diseases.
|
-
- HY-12760S
-
-
- HY-N3051
-
-
- HY-B0690
-
-
- HY-100254
-
-
- HY-15392
-
|
Chroman 1
|
ROCK
|
Cardiovascular Disease
|
|
Chroman 1 is a highly potent and selective ROCK inhibitor. Chroman 1 is more potent against ROCK2 (IC50=1 pM) than ROCK1 (IC50=52 pM). Chroman 1 also has inhibitory activity against MRCK, with an IC50 of 150 nM.
|
-
- HY-112075
-
-
- HY-W510159
-
-
- HY-B0162
-
|
Ivabradine
|
HCN Channel
|
Cardiovascular Disease
|
|
Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity.
|
-
- HY-128678
-
-
- HY-B1181A
-
-
- HY-U00172
-
|
Ipramidil
C80-1324
|
Others
|
Cardiovascular Disease
|
|
Ipramidil (C80-1324) is a furoxan compound. Ipramidil (C80-1324) reveals marked dilator activity in the coronary circulation of isolated working hearts.
|
-
- HY-107428
-
|
PD-166793
|
MMP
|
Cardiovascular Disease
|
|
PD-166793 is a potent, selective, orally active and wide‐broad spectrum inhibitor of MMP, exhibiting nanomolar potency against MMP-2, MMP-3 and MMP-13 (IC50=4, 7, and 8 nM, respectively) and micromolar potency vs MMP-1, -7 and -9 (IC50=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure.
|
-
- HY-A0230A
-
|
Spirapril hydrochloride
SCH 33844 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Spirapril (SCH 33844) hydrochloride is a potent angiotensin converting enzyme (ACE) inhibitor with antihypertensive activity. Spirapril competitively binds to ACE and prevents the conversion of angiotensin I to angiotensin II. Spirapril is an orally active proagent of Spiraprilat and can be used for the research of hypertension, congestive heart failure.
|
-
- HY-N10452
-
-
- HY-P2496
-
-
- HY-145611
-
-
- HY-B1014S1
-
-
- HY-P3142
-
-
- HY-10521
-
-
- HY-14187S
-
-
- HY-N0684S1
-
-
- HY-W011552
-
-
- HY-P3557
-
-
- HY-15876
-
-
- HY-124873
-
|
SERCA2a activator 1
|
Calcium Channel
|
Cardiovascular Disease
|
|
SERCA2a activator 1 (Compound A) is a sarco/endoplasmic reticulum Ca 2+-dependent ATPase 2a (SERCA2a) activator. SERCA2a activator 1 attenuates phospholamban inhibition and enhances the systolic and diastolic functions of the heart. SERCA2a activator 1 can be used for heart failure.
|
-
- HY-111098
-
-
- HY-116675
-
-
- HY-153489
-
|
ISIS 329993
ISIS-CRPRx
|
Others
|
Cardiovascular Disease
|
|
ISIS 329993 (ISIS-CRPRx) is an antisense oligonucleotide targeting to C-reactive protein (CRP). ISIS-CRPRx?has been tested in a rodent model of rheumatoid arthritis (RA) and was shown to improve the clinical signs of arthritis
|
-
- HY-105239
-
-
- HY-100937
-
|
DPCPX
PD 116948
|
Adenosine Receptor
|
Cardiovascular Disease
|
|
DPCPX (PD 116948), a xanthine derivative, is a highly potent and selective Adenosine A1 receptor antagonist, with a Ki of 0.46 nM in 3H-CHA binding to A1 receptors in rat whole brain membranes.
|
-
- HY-B0592S
-
-
- HY-108555
-
-
- HY-100720
-
-
- HY-101918
-
|
DS-1040 Tosylate
|
Others
|
Cardiovascular Disease
|
|
DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC50s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases.
|
-
- HY-101355B
-
-
- HY-106080A
-
|
Furegrelate sodium
U-63557A
|
Others
|
Cardiovascular Disease
|
|
Furegrelate Sodium (U-63557A) is a potent, orally available, and selective thromboxane synthase inhibitor. Furegrelate Sodium inhibits human platelet microsomal thromboxane A2 (TxA2) synthase with an IC50 of 15 nM. Furegrelate Sodium is being developed as an antiplatelet agent.
|
-
- HY-100960
-
|
Dioctanoylglycol
Ethylene glycol dicaprylate; Ethylene glycol dioctanoate; Ethylenedioctanoate
|
DGK
|
Cardiovascular Disease
|
|
Dioctanoylglycol (Ethylene glycol dicaprylate), a diacylglycerol analog, is a diacylglycerol kinase (DGK) inhibitor (Ki of 58 μM).
|
-
- HY-N5063
-
-
- HY-N0454
-
-
- HY-120516
-
|
CDE-096
|
PAI-1
|
Cardiovascular Disease
|
|
CDE-096 is a potent inhibitor of PAI-1. CDE-096 prevents PAI-1 from inactivating tPA and uPA with similar potency (IC50=30 and 25 nM, respectively) and is active against glycosylated PAI-1, as well as PAI-1 derived from several species (IC50=19, 22 and 18 nM for murine, rat, and Porcine PAI-1, respectively).
|
-
- HY-N4309A
-
|
Lotusine hydroxide
|
Others
|
Cardiovascular Disease
|
|
Lotusine (hydroxide) is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine (hydroxide) shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers.
|
-
- HY-106577
-
|
Cibenzoline
Cifenline; Ro 22-7796
|
Potassium Channel
|
Cardiovascular Disease
|
|
Cibenzoline is a potent inhibitor of KATP channel with directly affecting the pore-forming Kir6.2 subunit rather than the SUR1 subunit. Cibenzoline is a class Ia antiarrhythmic agent. Cibenzoline has little anticholinergic activity. Cibenzoline markedly attenuate LVPG which has a close relationship with myocardial contractility decreasing. Cibenzoline has the potential for the research of hypertrophic obstructive cardiomyopathy.
|
-
- HY-A0093S1
-
-
- HY-117658
-
|
GSK-114
|
Others
|
Cardiovascular Disease
|
|
GSK-114 is a highly selective, orally active TNNI3K inhibitor (IC50= 25 nM). GSK-114 shows a 40-fold selectivity for TNNI3K over B-Raf kinase (IC50= 1 µM). Cardiac troponin I-interacting kinase (TNNI3K or CARK) is a member of the tyrosine-like kinase family that is selectively expressed in heart tissue.
|
-
- HY-W017540
-
|
Cyclocreatine
|
Others
|
Cardiovascular Disease
|
|
Cyclocreatine is a Creatine analogue and acts as a potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine crosses membranes, enters the brain, and can be phosphorylated and dephosphorylated by creatine kinases.
|
-
- HY-N2073S
-
|
Ethyl linolenate-d5
|
MCHR1 (GPR24)
|
Cardiovascular Disease
|
|
Ethyl linolenate-d5 is the deuterium labeled Ethyl linolenate. Ethyl linolenate is a fatty acid ethyl ester (FAEE). Ethyl linolenate plays an active role in inhibition of the cellular production on melanin with an IC50 of 70 μM. Anti-melanogenesis Effects[1].
|
-
- HY-N0666S9
-
-
- HY-12593
-
|
GS967
|
Sodium Channel
|
Cardiovascular Disease
|
|
GS967 (GS-458967) is a potent, and selective inhibitor of cardiac late sodium current (late INa ) with IC50 values of 0.13 and 0.21 μM for ventricular myocytes and isolated hearts, respectively.
|
-
- HY-16915
-
|
RPR-260243
|
Potassium Channel
|
Cardiovascular Disease
|
|
RPR-260243, a potent activator of human ether-a-go-go-related gene (hERG), slows deactivation and attenuates inactivation of hERG1 channels. RPR260243-modified HERG currents are inhibited by Dofetilide (IC50=58 nM). RPR260243 displays no activator-like effects on other voltage-dependent ion channels, including the closely related ERG3 K+ channel.
|
-
- HY-B1061
-
-
- HY-B0312S
-
-
- HY-B0384
-
-
- HY-125643
-
-
- HY-U00201
-
-
- HY-12805
-
|
ML171
2-Acetylphenothiazine; 2-APT
|
NADPH Oxidase
|
Cardiovascular Disease
|
|
ML171 (2-Acetylphenothiazine;2-APT) is a potent and selective NADPH oxidase 1 (Nox1) inhibitor that blocks Nox1-dependent ROS generation, with an IC50 of 0.25 μM in HEK293-Nox1 confirmatory assay.
|
-
- HY-B1438
-
-
- HY-P9914
-
|
Eculizumab
Anti-Human C5, Humanized Antibody
|
Complement System
|
Cardiovascular Disease
|
|
Eculizumab (Anti-Human C5, Humanized Antibody) is a long-acting humanized monoclonal antibody targeted against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research.
|
-
- HY-19263
-
-
- HY-B1167
-
|
Ajmaline
Cardiorythmine; (+)-Ajmaline
|
Sodium Channel
|
Cardiovascular Disease
|
|
Ajmaline (Cardiorythmine) is a sodium channel blocking, class 1A anti-arrhythmic agent. Ajmaline blocks HERG currents with an IC50 of 1 μM in HEK cells and 42.3 μM in Xenopus oocytes. Ajmaline can be used for the research of the ventricular tachyarrhythmia.
|
-
- HY-101957
-
|
AG 1295
|
PDGFR
|
Cardiovascular Disease
|
|
AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor.
|
-
- HY-P4159
-
-
- HY-113986
-
|
Dexfadrostat
(R)-Fadrozole; (R)-CGS 16949A free base; FAD286
|
Others
|
Cardiovascular Disease
|
|
Dexfadrostat ((R)-Fadrozole) is a potent nonsteroidal inhibitor. Dexfadrostat also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. Dexfadrostat reverses cardiac fibrosis in spontaneously hypertensive heart failure rats..
|
-
- HY-114511
-
|
BMS-593214
|
Others
|
Cardiovascular Disease
|
|
BMS-593214 is an active site-directed factor (F) VIIa inhibitor. BMS-593214 shows antithrombotic and antihaemostatic properties. BMS-593214 is a direct competitive inhibitor of human FVIIa and a non-competitive inhibitor of Viia-activated substrate FX. BMS-593214 prevents electroinduced carotid artery thrombosis (AT) and wire induced vena cava thrombosis (VT).
|
-
- HY-18775
-
-
- HY-P0019
-
-
- HY-122908
-
|
Atuliflapon
AZD5718
|
FLAP
|
Cardiovascular Disease
|
|
Atuliflapon (AZD5718) is an orally active inhibitor of FLAP (5‑Lipoxygenase activating protein), with an IC50 of 2 nM. Atuliflapon is used in the study for coronary artery disease.
|
-
- HY-111655
-
|
SKA-31
|
Potassium Channel
|
Cardiovascular Disease
|
|
SKA-31 is a potent potassium channel activator with EC50s of 260 nM, 1.9 μM, 2.9 μM, and 2.9 μM for KCa3.1, KCa2.2, KCa2.1 and KCa2.3, respectively. SKA-31 potentiates endothelium-derived hyperpolarizing factor response and lowers blood pressure.
|
-
- HY-106554
-
-
- HY-100171
-
-
- HY-114953
-
-
- HY-108575
-
-
- HY-111755
-
|
Oral antiplatelet agent 1
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Oral antiplatelet agent 1 is a potent P2Y12 receptor antagonist. Oral antiplatelet agent 1 exhibits excellent antiplatelet aggregation potency with an IC50 value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. Oral antiplatelet agent 1 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. Oral antiplatelet agent 1 can be used to research thromboembolic disorders.
|
-
- HY-101205
-
-
- HY-105064B
-
|
Zoniporide hydrochloride
CP-597396 hydrochloride
|
Na+/H+ Exchanger (NHE)
|
Cardiovascular Disease
|
|
Zoniporide (CP-597396) hydrochloride is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM).
|
-
- HY-B1254
-
-
- HY-B0375S
-
-
- HY-W187973
-
-
- HY-B0968A
-
|
Trimetazidine
|
Autophagy
|
Cardiovascular Disease
|
|
Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor.
|
-
- HY-11021
-
|
Elinogrel
PRT060128
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Elinogrel (PRT060128) is a potent, direct acting, competitive, and reversible platelet P2Y12 antagonist (IC50=20 nM). It is orally and intravenously available and has potent antiplatelet effects.
|
-
- HY-50667S
-
|
Apixaban-13C,d3
BMS-562247-01-13C,d3
|
Factor Xa
|
Cardiovascular Disease
|
|
Apixaban- 13C,d3 is a deuterium and 13C labeled Apixaban. Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively[1].
|
-
- HY-15798
-
|
UNC2881
|
TAM Receptor
|
Cardiovascular Disease
|
|
UNC2881 is an orally active and specific Mer kinase inhibitor, inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. UNC2881 shows additional inhibition against Axl and Tyro with IC50s of 360 nM and 250 nM, respectively. UNC2881 potently inhibits collagen-induced platelet aggregation, can be used for pathologic thrombosis research.
|
-
- HY-P2090A
-
|
Angiopeptin TFA
|
Somatostatin Receptor
Adenylate Cyclase
|
Cardiovascular Disease
|
|
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst2/sst5 receptor partial agonist with IC50 values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research.
|
-
- HY-P3429
-
|
RNAENFDRF
|
PKC
|
Cardiovascular Disease
|
|
RNAENFDRF (βIIPKC624-632) is conjugated to the cell permeable peptide TAT47-57, which can be used to form an inhibitory peptide SAMβA. SAMβA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats.
|
-
- HY-109877
-
-
- HY-17567C
-
|
Heparin sodium salt (MW 15kDa)
Sodium heparin (MW 15kDa); Sodium heparinate (MW 15kDa)
|
Thrombin
Factor Xa
Autophagy
|
Cardiovascular Disease
|
|
Heparin sodium salt (MW 15kDa) (Sodium heparin (MW 15kDa)) is a polymer of Heparin with the molecular weight of 15kDa. Heparin sodium salt is an anticoagulant which binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin factor IIa and factor Xa.
|
-
- HY-12533
-
|
Disopyramide
Dicorantil; SC-7031
|
Sodium Channel
Potassium Channel
|
Cardiovascular Disease
|
|
Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action.
|
-
- HY-14255
-
-
- HY-N10199
-
-
- HY-14276A
-
|
Gallopamil hydrochloride
Methoxyverapamil hydrochloride
|
Calcium Channel
|
Cardiovascular Disease
|
|
Gallopamil hydrochloride (Methoxyverapamil hydrochloride), a methoxy derivative of Verapamil, is a phenylalkylamine calcium antagonist. Gallopamil hydrochloride inhibits acid secretion in a concentration-dependent manner with an IC50 of 10.9 μM. Gallopamil hydrochloride is a potent antiarrhythmic and vasodilator agent.
|
-
- HY-118969
-
-
- HY-19886
-
|
F 16915
|
Others
|
Cardiovascular Disease
|
|
F 16915, a Docosahexaenoic Acid (DHA, HY-B2167) derivative, is a potent pro-agent of DHA. F 16915 can prevent heart failure-induced atrial fibrillation.
|
-
- HY-P3346
-
-
- HY-W288642
-
-
- HY-128511
-
|
Piridoxilate
Piridoxylate
|
Others
|
Cardiovascular Disease
|
|
Piridoxilate (Piridoxylate), a glyoxylate derivative, is an anti-anoxic agent. Piridoxilate can be used in research on vascular diseases and coronary occlusion.
|
-
- HY-B2106
-
|
Polidocanol
Polyoxyethylene lauryl ether; Polyoxyethyleneglycol Dodecyl Ether
|
Others
|
Cardiovascular Disease
|
|
Polidocanol is a sclerosing agent used successfully to treat extremity and esophageal varices and telangiectasias.
|
-
- HY-U00218
-
-
- HY-103336
-
|
Tocrifluor 1117
T1117
|
GPR55
Cannabinoid Receptor
|
Cardiovascular Disease
|
|
Tocrifluor 1117 (T1117), a fluorescent form of the cannabinoid CB1 receptor antagonist AM251 (HY-15443), is a selective fluorescent GPR55 ligand. Tocrifluor 1117 is a potent tool for identifying the cellular location of cannabinoid receptors (including GPR55 in living tissues) (Ex/Em=543/590 nm).
|
-
- HY-W001940
-
-
- HY-113313S2
-
|
Aldosterone-d4
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Aldosterone-d4 is the deuterium labeled Aldosterone. Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by t
|
-
- HY-U00211
-
-
- HY-147425
-
-
- HY-109562A
-
|
CCG258208 hydrochloride
GRK2-IN-1 hydrochloride
|
G Protein-coupled Receptor Kinase (GRK)
|
Cardiovascular Disease
|
|
CCG258208 (GRK2-IN-1) hydrochloride is a potent and selective GRK2 (G protein-coupled receptor kinase 2) inhibitor (IC50=30 nM) while maintaining 230-fold selectivity over GRK5 (IC50=7.09 μM) and more than 2500-fold selectivity over GRK1 (IC50=87.3 μM), PKA, and ROCK1. CCG258208 hydrochloride can be used in heart failure research.
|
-
- HY-15392A
-
|
Chroman 1 dihydrochloride
|
ROCK
|
Cardiovascular Disease
|
|
Chroman 1 dihydrochloride is a highly potent and selective ROCK inhibitor. Chroman 1 dihydrochloride is more potent against ROCK2 (IC50=1 pM) than ROCK1 (IC50=52 pM).
Chroman 1 dihydrochloride also has inhibitory activity against MRCK, with an IC50 of 150 nM.
|
-
- HY-P3563
-
-
- HY-130272
-
|
Anti-MI/R injury agent 1
|
Others
|
Cardiovascular Disease
|
|
Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats.
|
-
- HY-B0309
-
|
Felodipine
|
Calcium Channel
Autophagy
|
Cardiovascular Disease
|
|
Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier.
|
-
- HY-B0006C
-
-
- HY-12345
-
|
ML365
|
Potassium Channel
|
Cardiovascular Disease
|
|
ML365 is a selective two-pore domain potassium channel KCNK3/TASK1 inhibitor, with an IC50 of 4 nM. ML365 acts as a pharmacological tool that can be used to examine the specific roles of TASK1 channels.
|
-
- HY-N0666D
-
-
- HY-108260
-
|
Deferitrin
GT-56-252
|
Others
|
Cardiovascular Disease
|
|
Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major.
|
-
- HY-N0666S4
-
-
- HY-B1448A
-
|
Benidipine
KW-3049 free base
|
Apoptosis
Calcium Channel
|
Cardiovascular Disease
|
|
Benidipine is a potent and orally active calcium channel antagonist. Benidipine shows anti-apoptosis effects in ischaemic/reperfused myocardial cells. Benidipine increases the activity of endothelial cell-type nitric oxide synthase and improves coronary circulation in hypertensive rats.
|
-
- HY-N1933
-
|
Allocryptopine
|
Potassium Channel
|
Cardiovascular Disease
|
|
Allocryptopine, a derivative of tetrahydropalmatine, is extracted from Macleaya cordata (Thunb.) Pers. Papaveraceae. Allocryptopine has antiarrhythmic effects and potently blocks human ether-a-go-go related gene (hERG) current.
|
-
- HY-135121
-
|
Ethacizine hydrochloride
Ethacizin; NIK-244
|
Sodium Channel
|
Cardiovascular Disease
|
|
Ethacizine hydrochloride (Ethacizin; NIK-244) is a longer-lasting Class Ic antiarrhythmic agent than Flecainide. Ethacizine hydrochloride (Ethacizin; NIK-244) inhibits the depolarizing current responsible for the intraatrial and His-Purkinje-ventricular conduction.
|
-
- HY-P1164
-
-
- HY-125554
-
-
- HY-10277
-
|
Odiparcil
SB-424323
|
Thrombin
|
Cardiovascular Disease
|
|
Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) .
|
-
- HY-135746
-
-
- HY-135388
-
|
ent-Ezetimibe
ent-SCH 58235
|
Drug Metabolite
|
Cardiovascular Disease
|
|
ent-Ezetimibe (ent-SCH 58235) is the RRS-enantiomer of Ezetimibe. Ezetimibe is a potent cholesterol absorption inhibitor. Ezetimibe is a Niemann-Pick C1-like1 (NPC1L1) inhibitor, and is a potent Nrf2 activator.
|
-
- HY-100713
-
-
- HY-101245
-
-
- HY-A0115
-
-
- HY-N2548
-
-
- HY-W011641
-
-
- HY-P1106A
-
|
K41498 TFA
|
CFTR
|
Cardiovascular Disease
|
|
K41498 TFA is a potent and highly selective CRF2 receptor antagonist with Ki values of 0.66 nM, 0.62 nM and 425 nM for human CRF2α, CRF2β and CRF1 receptors respectively. K41498 TFA is an analogues of antisauvagine-30 (aSvg-30), inhibits sauvagine-stimulated cAMP accumulation in hCRF2α- and hCRF2β-expressing cells. K41498 TFA can be used for hypotension study.
|
-
- HY-101415
-
|
Coenzyme Q9
Ubiquinone Q9; CoQ9; Ubiquinone 9
|
Apoptosis
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Coenzyme Q9 (Ubiquinone Q9), the major form of ubiquinone in rodents, is an amphipathic molecular component of the electron transport chain that functions as an endogenous antioxidant. Coenzyme Q9 attenuates the diabetes-induced decreases in antioxidant defense mechanisms. Coenzyme Q9 improves left ventricular performance and reduces myocardial infarct size and cardiomyocyte apoptosis.
|
-
- HY-N3919
-
|
γ-Methoxyisoeugenol
|
Others
|
Cardiovascular Disease
|
|
γ-Methoxyisoeugenol (Compound 5) is an anticoagulant agent that remarkably prolongs the thrombin time with a good dose-effect relationship at concentrations from 6.25 to 100 mM, but shows no significant differences in prothrombin time.
|
-
- HY-12778S
-
-
- HY-10268B
-
|
Betrixaban hydrochloride
PRT054021 hydrochloride
|
Factor Xa
|
Cardiovascular Disease
|
|
Betrixaban (PRT054021) hydrochloride is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban hydrochloride shows antithrombotic effect.
|
-
- HY-12378
-
|
BQ-123
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
BQ-123 is a potent and selective endothelin A (ETA) receptor antagonist with an IC50 of 7.3 nM and a Ki of 25 nM. BQ-123 inhibits endothelin-1-mediated proliferation of human pulmonary artery smooth muscle cells and lowers blood pressure in different rat models of hypertension.
|
-
- HY-B0341
-
|
Nicorandil
SG-75
|
Potassium Channel
|
Cardiovascular Disease
|
|
Nicorandil (SG-75) is a potent potassium channel activator and targets vascular nucleoside diphosphate-dependent K + channels and cardiac ATP-sensitive K + channels (KATP). Nicorandil is a nicotinamide ester with vasodilatory and cardioprotective effects and has the potential for angina and forischemic heart diseases.
|
-
- HY-123846
-
|
MLS-0437605
|
Phosphatase
|
Cardiovascular Disease
|
|
MLS-0437605 is a selective dual-specificity phosphatase 3 (DUSP3) inhibitor with an IC50 of 3.7 μM. MLS-0437605 is more selective for DUSP3 than DUSP22 and other protein tyrosine phosphatases (PTPs).
|
-
- HY-14993
-
|
SCH79797
|
Protease Activated Receptor (PAR)
Apoptosis
|
Cardiovascular Disease
|
|
SCH79797 is a highly potent, selective nonpeptide protease activated receptor 1 (PAR1) antagonist. SCH79797 inhibits binding of a high-affinity thrombin receptor-activating peptide to PAR1 with an IC50 of 70 nM and a Ki of 35 nM. SCH79797 inhibits thrombin-induced platelet aggregation with an IC50 of 3 μM. SCH79797 has antiproliferative and pro-apoptotic effects, and limits myocardial ischemia/reperfusion injury in rat hearts. SCH79797 also potently prevents PAR1 activation in vascular smooth muscle cells, endothelial cells, and astrocytes.
|
-
- HY-10163S
-
|
Dabigatran-d4
BIBR 953-d4; BIBR 953ZW-d4
|
Thrombin
|
Cardiovascular Disease
|
|
Dabigatran-d4 is deuterium labeled Dabigatran. Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM)[1][2].
|
-
- HY-121018
-
|
Daltroban
BM-13505; SKF 96148
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Daltroban (BM-13505) is a selective and specific thromboxane A2 (TXA2) receptor antagonist. Daltroban increase intracellular calcium in vascular smooth muscle cells. Daltroban shows protective effect in reperfusion injury.
|
-
- HY-115748A
-
-
- HY-100594
-
|
EUK-134
|
NF-κB
|
Cardiovascular Disease
|
|
EUK-134, a synthetic superoxide dismutase and catalase mimetic, protects rat kidneys from ischemia-reperfusion-induced damage. EUK-134 is a superoxide dismutase (SOD) mimetics (SODm) with catalase activity. EUK-134 is a mitoprotective antioxidant. EUK-134 reduces the expression of NF-κB, MDA level, and protein carbonylation in H9C2 cells.
|
-
- HY-116078
-
|
CKD-519
|
CETP
|
Cardiovascular Disease
|
|
CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor, which inhibits CETP-mediated transfer of cholesteryl ester in human serum with an IC50 of 2.3 nM.
|
-
- HY-144801
-
|
DDO-02005 free base
|
Potassium Channel
|
Cardiovascular Disease
|
|
DDO-02005 (free base) is a potent Kv1.5 potassium channel inhibitor with an IC50 value of 0.72 μM. DDO-02005 (free base) has good anti-atrial fibrillation (AF) effect in CaCl2-ACh AF rats model and effective anti-arrhythmic activity caused by aconitine.
|
-
- HY-148480
-
-
- HY-P3429A
-
|
RNAENFDRF TFA
|
PKC
|
Cardiovascular Disease
|
|
RNAENFDRF (βIIPKC624-632) TFA is conjugated to the cell permeable peptide TAT47-57, which can be used to form an inhibitory peptide SAMβA. SAMβA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats.
|
-
- HY-19354
-
|
Aglafoline
Aglafolin; Rocaglamide U; (-)-Methyl rocaglate
|
Others
|
Cardiovascular Disease
|
|
Aglafoline inhibits in a selective and concentration-dependent manner the aggregation and ATP release reaction induced in washed rabbit platelets by PAF (platelet-activating factor).
|
-
- HY-100986
-
|
L-NIO dihydrochloride
|
NO Synthase
|
Cardiovascular Disease
|
|
L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor, with Kis of 1.7, 3.9, 3.9 μM for neuronal (nNOS), endothelial (eNOS), and inducible (iNOS), respectively. L-NIO dihydrochloride induces a consistentfocal ischemic infarctin rats.
|
-
- HY-134005
-
-
- HY-111587
-
|
Ifenprodil glucuronide
|
Others
|
Cardiovascular Disease
|
|
Ifenprodil glucuronide is a derivative of Ifenprodil. Ifenprodil is a vasodilator and an inhibitor of platelet aggregation, and Ifenprodil glucuronide has no effect on platelet aggregation and arterial contraction.
|
-
- HY-145633
-
|
Sozinibercept
OPT 302; VGX-300
|
VEGFR
|
Cardiovascular Disease
|
|
Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats.
|
-
- HY-112143
-
-
- HY-122543
-
-
- HY-108573
-
|
P-1075
|
Potassium Channel
|
Cardiovascular Disease
|
|
P-1075 is a potent activator of sulfonylurea receptor 2-associated ATP-sensitive potassium channels (SUR2-KIR6), with an EC50 value of 45 nM for SUR2B-KIR6 channel activation. P-1075 also P1075 opens mitochondrial K(ATP) channels and generates reactive oxygen species resulting in cardioprotection of rabbit hearts.
|
-
- HY-112202
-
-
- HY-P2196
-
-
- HY-N1208
-
|
Spiradine F
O-Acetylspiradine G; Spiradine G acetate
|
Others
|
Cardiovascular Disease
|
|
Spiradine F is a main alkaloidal component of spiraea japonioa L. fil. Spiradine F derivative can inhibit platelet-activating factor (PAF)-induced platelet aggregation.
|
-
- HY-115831
-
|
SAR247799
S1P1 agonist 3
|
LPL Receptor
|
Cardiovascular Disease
|
|
SAR247799 (S1P1 agonist 3) is an oral activity, selective G-protein-biased sphingosine-1 phosphate receptor-1 (S1P1 ) agonist, with EC50s rang from 12.6 to 493 nM in S1P1-overexpressing cells and HUVECs. SAR247799 can be used for the research of endothelial protection, including type-2 diabetes, metabolic syndrome.
|
-
- HY-106523
-
|
Nipradolol
KT 210; K 351; Hypadil
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Nipradolol (KT-210; K-351) is a potent blocker of alpha-1-adrenergic receptors. Nipradolol inhibits the increase of intraocular pressure (IOP) in an albino rabbit model induced by Phenylephrine (HY-B0769). Nipradolo suppresses the noradrenaline (NA)-induced muscles contraction, also exhibits vasodilator activity on the dog coronary artery.
|
-
- HY-N7614
-
|
Anemarrhenasaponin A2
Schidigerasaponin F2; Timosaponin AII
|
Others
|
Cardiovascular Disease
|
|
Anemarrhenasaponin A2 (Schidigerasaponin F2) is a steroidal saponin isolated from the rhizomes of Anemarrhena asphodeloides. Anemarrhenasaponin A2 inhibits ADP-induced platelet aggregation.
|
-
- HY-P3136A
-
-
- HY-134686
-
|
Edoxaban impurity 4
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
|
Edoxaban impurity 4 is an impurity of Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention.
|
-
- HY-135363
-
-
- HY-B0006BS
-
|
(S)-Carvedilol-d4
(S)-BM 14190-d4
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
(S)-Carvedilol-d4 is deuterium labeled (S)-Carvedilol. (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1].
|
-
- HY-Q22471
-
|
ROCK1-IN-1
|
ROCK
|
Cardiovascular Disease
|
|
ROCK1-IN-1 is a ROCK1 inhibitor with a Ki value of 540 nM. ROCK1-IN-1 can be used for the research of hypertension, glaucoma and erectile dysfunction.
|
-
- HY-147751
-
-
- HY-108658
-
|
MRS2500 tetraammonium
|
P2Y Receptor
|
Cardiovascular Disease
|
|
MRS2500 tetraammonium is a potent, selective and stable antagonist of the P2Y1 receptor (Ki=0.78 nM for recombinant human P2Y1 receptor). MRS2500 tetraammonium inhibits the ADP-induced aggregation of human platelets with an IC50 value of 0.95 nM. Antithrombotic activity.
|
-
- HY-B1170
-
-
- HY-136346S
-
-
- HY-16056
-
|
Arbutamine
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Arbutamine is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine can be used for cardiac stress agent .
|
-
- HY-126653
-
-
- HY-B2087
-
-
- HY-129851
-
|
NTP42
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
NTP42 is a thromboxane A2 (TXA2) receptor antagonist with an IC50 of 3.278 nM for antagonizing T prostanoid receptor (TP)- mediated [Ca 2+] mobilization following stimulation of cells with the alternative TP agonist U46619. NTP42 can be used for the treatment of pulmonary arterial hypertension (PAH).
|
-
- HY-B0772A
-
-
- HY-B0432A
-
-
- HY-B1364
-
-
- HY-116868
-
|
Anecortave acetate
Anecortave
|
PAI-1
|
Cardiovascular Disease
|
|
Anecortave acetate is a potent ocular angiostatic agent. Anecortave acetate inhibits neovascularization which is induced by many different angiogenic factors, and increases plasminogen activator inhibitor-1 (PAI-1) mRNA expression. Anecortave acetate can be used to research ocular neovascular diseases.
|
-
- HY-151996
-
-
- HY-100655
-
-
- HY-100400A
-
-
- HY-N2509
-
|
Iristectorigenin B
Iristectrigenin B
|
LXR
|
Cardiovascular Disease
|
|
Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β.
|
-
- HY-151196
-
-
- HY-120355A
-
|
AP14145 hydrochloride
|
Potassium Channel
|
Cardiovascular Disease
|
|
AP14145 hydrochloride is a potent KCa2 (SK) channel negative allosteric modulator with an IC50 of 1.1 μM for KCa2.2 (SK2) and KCa2.3 (SK3) channels. AP14145 hydrochloride inhibition strongly depends on two amino acids, S508 and A533 in the channel. AP14145 hydrochloride prolonged atrial effective refractory period (AERP) in rats and demonstrates antiarrhythmic effects in a Vernakalant-resistant porcine model of atrial fibrillation (AF).
|
-
- HY-132583
-
-
- HY-B0918
-
-
- HY-126195
-
|
Fluoflavine
ML-090
|
NADPH Oxidase
|
Cardiovascular Disease
|
|
Fluoflavine (ML-090) is a selective NOX1 inhibitor with an IC50 of 90 nM. Fluoflavine has >100 selectivity for NOX1 over NOX2, NOX3, NOX4 (all IC50>10 μM). ML-090 has an IC50 of 360 nM in HEK293 cells.
|
-
- HY-123368
-
-
- HY-107579
-
|
Acifran
AY 25712
|
GPR109A
|
Cardiovascular Disease
|
|
Acifran (AY 25712), an antihyperlipidemic agent, is an orally active agonist of GPR109A (HM74A) and GPR109B, the high and low affinity receptors for Niacin.
|
-
- HY-N0666B
-
-
- HY-113375
-
-
- HY-P1164A
-
-
- HY-108494
-
|
CYM50260
|
LPL Receptor
|
Cardiovascular Disease
|
|
CYM50260 is a potent and exquisitely selective sphingosine-1-phosphate 4 receptor (S1P4-R) agonist with an EC50 of 45 nM. CYM50260 displays no activity against S1P1-R, S1P2-R, S1P3-R and S1P5-R.
|
-
- HY-18208
-
-
- HY-N5049
-
-
- HY-145610
-
-
- HY-108656
-
|
MRS2365
|
P2Y Receptor
Arrestin
|
Cardiovascular Disease
|
|
MRS2365 is a potent and selective P2Y1 receptor (EC50=0.4 nM) /[ 35S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC50 of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors.
|
-
- HY-B0023
-
-
- HY-112499S
-
|
Menaquinone-7-d7
Vitamin K2-7-d7; Vitamin K2(35)-d7; Vitamin MK-7-d7
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
Menaquinone-7-d7 is the deuterium labeled Menaquinone-7. Menaquinone-7 (Vitamin K2-7), belongs to a class of K2-vitamin homologs, is originally discovered as the anti-hemorrhagic factors[1]. Menaquinone-7 (Vitamin K2-7) is identified as the most bioactive cofactor for the carboxylation reaction of Gla-proteins [2]. Supplementation with Menaquinone-7 (Vitamin K2-7) is a pharmacological option for activating matrix Gla protein and intervening in the progression of calcific aortic valve stenosis (CAVS)[3].
|
-
- HY-111372
-
|
Finerenone
BAY 94-8862
|
Mineralocorticoid Receptor
|
Cardiovascular Disease
|
|
Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC50=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease.
|
-
- HY-N11322
-
|
Bitis Arietans Venom
Puff Adder Venom
|
Others
|
Cardiovascular Disease
|
|
Bitis Arietans Venom (Puff Adder Venom) is a snake venom that can be obtained from Bitis Arietans. Bitis Arietans Venom inhibits platelet aggregation. The fibrinogenase can be purified from the Bitis Arietans Venom, and cleaves the Aα and Bβ chain of fibrinogen.
|
-
- HY-B0924
-
-
- HY-148687
-
|
SPC5001
|
Others
|
Cardiovascular Disease
|
|
SPC5001 is a locked nucleic acid (LNA)-modifed antisense oligonucleotide (ASO) complementary to human PCSK9 (proprotein convertase subtilisin/kexin type 9) mRNA. SPC5001 can be used for the research of hypercholesterolemia. SPC5001 sequence: 5′-TGmCTACAAAACmCmCA-3′.
|
-
- HY-N6868
-
-
- HY-P1536
-
-
- HY-10655A
-
|
Palosuran hydrochloride
ACT-058362 hydrochloride
|
Urotensin Receptor
|
Cardiovascular Disease
|
|
Palosuran hydrochloride (ACT-058362 hydrochloride) is a potent, selective, and orally active antagonist of urotensin II receptor, with an IC50 of 3.6 nM for CHO cell membranes expressing human recombinant receptors. Palosuran hydrochloride can improves pancreatic and renal function in diabetic rats.
|
-
- HY-N0666S6
-
-
- HY-B0612AS1
-
|
Lercanidipine-13C,d3-1 hydrochloride
|
Calcium Channel
|
Cardiovascular Disease
|
|
Lercanidipine- 13C,d3-1 (hydrochloride) is deuterium labeled Lercanidipine (hydrochloride). Lercanidipine hydrochloride is a lipophilic third-generation dihydropyridine-calcium channel blocker (DHP-CCB). Lercanidipine hydrochloride has long lasting antihypertensive action and reno-protective effect[1][2][3].
|
-
- HY-108467
-
|
GGsTop
Nahlsgen
|
Others
|
Cardiovascular Disease
|
|
GGsTop (Nahlsgen) is a potent, non-toxic, highly selective and irreversible γ−glutamyl transpeptidase (GGT) inhibitor, with a Ki of 170 μM for Human GGT. GGsTop shows a pKa of 9.71, also exhibits Kons of 150±10 and 51±3 M -1 s -1 against E.coli GGT and human GGT, respectively. GGsTop protects hepatic ischemia-reperfusion injury in rat model.
|
-
- HY-10314
-
-
- HY-B0735
-
-
- HY-132670S
-
|
(R)-(-)-Felodipine-d5
|
Calcium Channel
Autophagy
|
Cardiovascular Disease
|
|
(R)-(-)-Felodipine-d5 is the deuterium labeled (R)-(-)-Felodipine. (R)-(-)-Felodipine is the S enantiomer of Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier[1][2][3].
|
-
- HY-P1471
-
-
- HY-117239
-
|
SB-206606
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
SB-206606, a stereoisomer of BRL 37344, is a potentially specific, beta 3-adrenergic receptor (β3-AR) ligand. The affinity of [3H]SB 206606 is 76 times higher for the β3-AR than for the beta 1/beta 2-adrenergic receptors.
|
-
- HY-123538
-
-
- HY-B0224S
-
-
- HY-B1486A
-
-
- HY-B1742
-
-
- HY-I0400S1
-
-
- HY-14656S
-
-
- HY-121460
-
-
- HY-15293B
-
|
JTV-519 hemifumarate
K201 hemifumarate
|
Calcium Channel
|
Cardiovascular Disease
|
|
JTV-519 hemifumarate (K201 hemifumarate) is a Ca 2+-dependent blocker of sarcoplasmic reticulum Ca 2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle. Antiarrhythmic and cardioprotective properties.
|
-
- HY-130353
-
|
Desethylamiodarone hydrochloride
N-desethylamiodarone hydrochloride; LB 33020 hydrochloride
|
Potassium Channel
Autophagy
|
Cardiovascular Disease
|
|
Desethylamiodarone hydrochloride (N-desethylamiodarone hydrochloride) is a major active metabolite of Amiodarone. Desethylamiodarone hydrochloride is formed by CYP3A isoenzymes. Amiodarone is an antiarrhythmic agent for inhibition of ATP-sensitive potassium channel with an IC50 of 19.1 μM.
|
-
- HY-103174
-
|
MRS1334
|
Adenosine Receptor
|
Cardiovascular Disease
|
|
MRS1334 is a potent and selective human adenosine A3 receptor antagonist with Kis of 2.69 nM, >100 nM, >100 nM for hA3, rA1, rA2A, respectively. MRS1334 blocks the protective effect of Cl-IB-MECA leading to significant bradycardia and elevated ST segment.
|
-
- HY-105666
-
-
- HY-16056A
-
|
Arbutamine hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Arbutamine hydrochloride is a short-acting, potent and nonselective β-adrenoceptor agonist. Arbutamine hydrochloride stimulates cardiac β1-, tracheal β2-, and adiopocyte β3- adrenergic receptors. Arbutamine hydrochloride provides cardiac stress increases heart rate, cardiac contractility, and systolic blood pressure. Arbutamine hydrochloride can be used for cardiac stress agent .
|
-
- HY-135328S
-
-
- HY-107414
-
-
- HY-14739
-
|
Choline Fenofibrate
ABT-335
|
PPAR
COX
|
Cardiovascular Disease
|
|
Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect.
|
-
- HY-P1214
-
-
- HY-10270
-
|
Flovagatran
TGN 255
|
Thrombin
|
Cardiovascular Disease
|
|
Flovagatran (TGN 255) is a potent and reversible thrombin inhibitor (Ki: 9 nM). Flovagatran can be used in the research of arterial and venous thrombosis.
|
-
- HY-66010A
-
|
Cinepazide
|
Calcium Channel
|
Cardiovascular Disease
|
|
Cinepazide is a piperazine derivative and acts as a weak calcium channel blocker. Cinepazide is a potent vasodilator and can be used for the research of cerebrovascular diseases, including ischemic stroke, brain infarct et. al.
|
-
- HY-N7671
-
-
- HY-17369B
-
|
Tirofiban
L700462; MK383
|
Integrin
|
Cardiovascular Disease
|
|
Tirofiban (L700462) is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area.
|
-
- HY-145349
-
-
- HY-U00135
-
-
- HY-B0382
-
-
- HY-10274A
-
|
Dabigatran etexilate mesylate
BIBR 1048MS; Dabigatran etexilate methanesulfonate
|
Thrombin
|
Cardiovascular Disease
|
|
Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.
|
-
- HY-109066
-
-
- HY-100145
-
-
- HY-101423
-
-
- HY-18600A
-
-
- HY-70035
-
|
Otamixaban
FXV673
|
Factor Xa
|
Cardiovascular Disease
|
|
Otamixaban(FXV673) is a potent (Ki = 0.5 nM), selective, rapid acting, competitive and reversible fXa inhibitor that effectively inhibits both free and prothrombinase-bound fXa.
|
-
- HY-117549
-
|
Ibrolipim
NO-1886
|
Others
|
Cardiovascular Disease
|
|
Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects.
|
-
- HY-131278
-
-
- HY-113313
-
|
Aldosterone
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by the zona glomerulosa (ZG) of the adrenal cortex. Aldosterone activity is dependent by the binding and activation of the cytoplasmic/nuclear mineralocorticoid receptor (MR) at cellular level.
|
-
- HY-18205
-
-
- HY-137446
-
-
- HY-109121
-
|
Reldesemtiv
CK-2127107
|
Others
|
Cardiovascular Disease
|
|
Reldesemtiv (CK-2127107) is a selective, orally active and next-generation fast skeletal muscle troponin activator (FSTA). Reldesemtiv selectively activates fast skeletal myofibrils with an EC50 of 3.4 μM. Reldesemtiv increases exercise performance in a heart failure model.
|
-
- HY-P4641
-
|
H-Trp-Phe-OH
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
H-Trp-Phe-OH is a dipeptide consisting of tryptophan and phenylalanine (Trp-Phe). H-Trp-Phe-OH is also an antihypertensive peptide with inhibitory activity on angiotensin-converting enzyme (ACE), dose-dependently increases NO levels, and decreases endothelin-1 (ET-1) levels. H-Trp-Phe-OH (2 mg/kg; subcutaneous injection; 6 injections over 3 days) causes an increase in ovarian weight in female mice.
|
-
- HY-148055
-
-
- HY-W195048
-
-
- HY-113517
-
-
- HY-15284
-
|
Prasugrel
PCR 4099
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Prasugrel (PCR 4099), a thienopyridine and proagent, inhibits platelet function. Prasugrel is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
|
-
- HY-101759
-
-
- HY-A0154
-
|
Deslanoside
Deacetyllanatoside C; Desacetyllanatoside C
|
Na+/K+ ATPase
Drug Metabolite
|
Cardiovascular Disease
|
|
Deslanoside (Desacetyllanatoside C) is a rapidly acting cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations .
|
-
- HY-50848
-
|
BW A868C
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
BW A868C, a hydantoin compound, is a BW245C structural analogue. BW A868C is a selective and potent competitive prostaglandin D2 (PGD2) antagonist. BW A868C has no effect on other prostaglandin receptors (IP, EP1, EP2, TP and FP).
|
-
- HY-A0126
-
|
Epoprostenol
Prostaglandin I2; Prostacyclin
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Epoprostenol (Prostaglandin I2), the synthetic form of the natural prostaglandin derivative Prostacyclin (Prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH. Epoprostenol is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation.
|
-
- HY-N4213
-
-
- HY-117743S
-
|
Eprosartan-d3
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Eprosartan-d3 is the deuterium labeled Eprosartan. Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensin II receptor antagonist, used as an antihypertensive. Eprosartan binds angiotensin II receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively [1].
|
-
- HY-P1471A
-
|
Adrenomedullin (AM) (22-52), human TFA
22-52-Adrenomedullin (human) (TFA)
|
CGRP Receptor
|
Cardiovascular Disease
|
|
Adrenomedullin (AM) (22-52), human (22-52-Adrenomedullin human) TFA, an NH2 terminal truncated adrenomedullin analogue, is an adrenomedullin receptor antagonist. Adrenomedullin (AM) (22-52), human also antagonizes the calcitonin generelated peptide (CGRP) receptor in the hindlimb vascular bed of the cat.
|
-
- HY-128889
-
-
- HY-100873
-
-
- HY-N6084
-
|
Humulone
α-Lupulic acid
|
COX
GABA Receptor
Apoptosis
|
Cardiovascular Disease
|
|
Humulone (α-Lupulic acid), a prenylated phloroglucinol derivative, is a potent cyclooxygenase-2 (COX-2) inhibitor. Humulone acts as a positive modulator of GABAA receptor at low micromolar concentrations. Humulone is an inhibitor of bone resorption. Humulone possesses antioxidant, anti-angiogenic and apoptosis-inducing properties.
|
-
- HY-118472
-
|
Benazeprilat
CGS 14831
|
Endogenous Metabolite
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Benazeprilat is an orally active and the active metabolite of benazepril, a carboxyl-containing ACE inhibitor with antihypertensive activity. Benazepril is a well-established antihypertensive agent, both in monoresearch and in combination with other classes of drugs including thiazide diuretics and calcium channel blockers. Benazepril is a first-line research in reducing various pathologies associated with CV risk and secondary end-organ damage.
|
-
- HY-Z0081
-
-
- HY-14834A
-
-
- HY-B0655
-
-
- HY-10273
-
|
Atecegatran metoxil
AZD0837; Atecegatran fexenetil
|
Thrombin
|
Cardiovascular Disease
|
|
Atecegatran metoxil is a oral anticoagulant, which inhibits thrombin factor II and is used in thromboembolic disorders. In vivo, Atecegatran metoxil is converted to AR-H067637, a selective and reversible direct thrombin inhibitor.
|
-
- HY-101016
-
|
17-ODYA
|
Cytochrome P450
Apoptosis
|
Cardiovascular Disease
|
|
17-ODYA is a CYP450 ω-hydroxylase inhibitor. 17-ODYA is also a potent inhibitor (IC50<100 nM) of the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids by rat renal cortical microsomes incubated with arachidonic acid. 17-ODYA completely attenuates the isoproterenol (ISO)-induced apoptosis, and necrosis in cultured cardiomyocytes.
|
-
- HY-146205
-
-
- HY-A0115S1
-
-
- HY-120006A
-
|
(rel)-AR234960
|
ERK
|
Cardiovascular Disease
|
|
(rel)-AR234960 is an active relative configuration of AR234960. AR234960, a non-peptide MAS (a G protein-coupled receptor) agonist, increases both mRNA and protein levels of CTGF via ERK1/2 signaling in HEK293-MAS cells and adult human cardiac fibroblasts.
|
-
- HY-15718A
-
-
- HY-111346
-
-
- HY-100662
-
-
- HY-Y0882
-
-
- HY-100718
-
|
SCH00013
|
Others
|
Cardiovascular Disease
|
|
SCH00013 is a cardiotonic agent that primarily acts via an increase in myofibrillar Ca++ sensitivity, have a significant Ca(2+)sensitizing effect at pH 7.2 to 7.4.
|
-
- HY-101232
-
|
Tiotidine
ICI 125211
|
Histamine Receptor
|
Cardiovascular Disease
|
|
Tiotidine (ICI 125211) is a potent and selective antagonist of histamine H2-receptor (pA2=7.3-7.8 for guinea-pig right atrium). Tiotidine has low affinity for both the H1 and the H3 receptors.
|
-
- HY-P0139
-
|
Gap 27
|
Gap Junction Protein
|
Cardiovascular Disease
|
|
Gap 27, a synthetic connexin43 mimetic peptide, is a gap junction inhibitor. Gap 27 possesses conserved sequence homology to a portion of the second extracellular loop leading into the fourth transmembrane connexin segment.
|
-
- HY-12654
-
-
- HY-P2249
-
|
ELA-21 (human)
|
Apelin Receptor (APJ)
Arrestin
|
Cardiovascular Disease
|
|
ELA-21 (human) is an apelin receptor agonist with a pKi of 8.52. ELA-21 (human) completely inhibits Forskolin-induced cAMP production and stimulates β-arrestin recruitment with subnanomolar potencies. ELA-21 (human) is an agonist in G-protein-dependent and -independent pathways.
|
-
- HY-15553A
-
-
- HY-P3162
-
-
- HY-P99631
-
|
Garadacimab
CSL312
|
Factor Xa
|
Cardiovascular Disease
|
|
Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research.
|
-
- HY-101529
-
|
Imanixil
HOE-402(free base)
|
LDLR
|
Cardiovascular Disease
|
|
Imanixil (HOE-402 free base) is an inducer of the LDL receptor (LDLR). Imanixil (HOE-402 free base) is also a potent cholesterol-lowering compound, which inhibits very low density-lipoprotein (VLDL) production, and consequently attenuates atherosclerosis development.
|
-
- HY-137431
-
|
Asundexian
BAY-2433334
|
Factor Xa
|
Cardiovascular Disease
|
|
Asundexian (BAY 2433334) is an orally active coagulation factor Xia (FXIa) inhibitor. Asundexian binds directly, potently, and reversibly to the active site of FXIa and thereby inhibits its activity. Asundexian inhibits human FXIa in buffer with an IC50 of 1 nM.
|
-
- HY-P1071A
-
-
- HY-P1275
-
-
- HY-B0612ES
-
-
- HY-19414
-
-
- HY-N0377A
-
|
(±)-Liquiritigenin
(±)-4',7-Dihydroxyflavanone
|
Reactive Oxygen Species
|
Cardiovascular Disease
|
|
(±)-Liquiritigenin ((±)-4',7-Dihydroxyflavanone) is isolated from Angelica keiskei, a hardy perennial herb of the Umbelliferae family. (±)-Liquiritigenin promotes cell proliferation, has cytoprotective activity and reduces cytotoxicity, and also has antioxidant stress effects.
|
-
- HY-12753A
-
|
Debutyldronedarone hydrochloride
SR35021 hydrochloride
|
Thyroid Hormone Receptor
|
Cardiovascular Disease
|
|
Debutyldronedarone (SR35021) hydrochloride, the main metabolite of Dronedarone, is a selective thyroid hormone receptor α1 (TRα1) inhibitor. Debutyldronedarone hydrochloride inhibits T3 binding to TRα1 and TRβ1 by 77% and 25%, respectively. Debutyldronedarone hydrochloride can be used for the research of arrhythmic.
|
-
- HY-W001583
-
-
- HY-13236
-
-
- HY-131276
-
-
- HY-101720A
-
-
- HY-106561
-
-
- HY-19254
-
|
ZD-0892
|
Elastase
|
Cardiovascular Disease
|
|
ZD-0892 is a selective and potent inhibitor of a neutrophil elastase with Kis of 6.7 and 200 nM for human neutrophil elastase and porcine pancreatic elastase, respectively.
|
-
- HY-B0968S
-
|
Trimetazidine-d8 dihydrochloride
|
Autophagy
|
Cardiovascular Disease
|
|
Trimetazidine-d8 (dihydrochloride) is the deuterium labeled Trimetazidine dihydrochloride. Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit β-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].
|
-
- HY-N0899
-
-
- HY-N0684S
-
-
- HY-113926
-
|
BAY 60-2770
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
BAY 60-2770 is a potent, selective, and orally active soluble guanylyl cyclase (sGC) activator. BAY 60-2770 increases the activity of sGC in a nitric oxide-independent manner. BAY 60-2770 shows antifibrotic effect.
|
-
- HY-106816
-
-
- HY-P2539
-
-
- HY-124031
-
-
- HY-109549
-
|
Desirudin
CGP 39393; Revasc
|
Thrombin
|
Cardiovascular Disease
|
|
Desirudin (CGP 39393) is a thrombin inhibitor. Desirudin can inhibit the formation of blood clots and venous stasis thrombosis, which is used for the research of thrombocytopenia or platelet dysfunction.
|
-
- HY-118044
-
-
- HY-U00344
-
-
- HY-16774
-
-
- HY-105686
-
-
- HY-U00209
-
-
- HY-128561
-
-
- HY-117281S
-
-
- HY-A0093
-
-
- HY-101327A
-
|
Xamoterol hemifumarate
Corwin hemifumarate; ICI 118587 hemifumarate
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Xamoterol hemifumarate is a selective and potent agonist of beta1-adrenergic receptor. Xamoterol hemifumarate has the potential for the research of arrhythmogenesis. Xamoterol hemifumarate has the potential for the investigating the relationship between β1-adrenergic stimulation and IKr.
|
-
- HY-106961
-
|
ONO 1301
ONO-AP 500-02
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig.
|
-
- HY-145354
-
-
- HY-14917
-
-
- HY-13289
-
|
Nepicastat
SYN117; RS-25560-197
|
Dopamine β-hydroxylase
|
Cardiovascular Disease
|
|
Nepicastat (SYN117) is a selective, potent, and orally active inhibitor of dopamine-beta-hydroxylase. Nepicastat (SYN117) produces concentration-dependent inhibition of bovine (IC50=8.5 nM) and human (IC50=9 nM) dopamine-beta-hydroxylase. Nepicastat (SYN117) can cross the blood-brain barrier (BBB).
|
-
- HY-19396
-
|
Ingliforib
CP 368296; GPi 296
|
Others
|
Cardiovascular Disease
|
|
Ingliforib (CP 368296) is a glycogen phosphorylase inhibitor, with IC50s of 52, 352 and 150 nM for liver, muscle and brain glycogen phosphorylase, and has cardioprotective activity.
|
-
- HY-118332
-
-
- HY-14186
-
|
KVI-020
WYE-160020
|
Potassium Channel
|
Cardiovascular Disease
|
|
KVI-020 is an orally active, potent and selective blocker of the atrial potassium channel Kv1.5, with an IC50 of 480 nM. KVI-020 can inhibits hERG, with an IC50 of 15100 nM. KVI-020 is a potent antiarrhythmic agent, and can be used for atrial fibrillation (AF) research.
|
-
- HY-108656A
-
-
- HY-125989
-
|
2-Methylthio-AMP
2-MeSAMP; 2-Methylthioadenosine 5′-monophosphate; 2-Methylthioadenosine 5′-phosphate
|
P2Y Receptor
|
Cardiovascular Disease
|
|
2-Methylthio-AMP (2-MeSAMP) is a selective and direct P2Y12 antagonist. 2-Methylthio-AMP is an inhibitor of ADP-dependent platelet aggregation.
|
-
- HY-114672
-
|
MBCQ
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
MBCQ is a potent and selective cGMP-specific phosphodiesterase (PDE V; PDE5) inhibitor with an IC50 of 19 nM. MBCQ lacks inhibitory activity toward other PDE isozymes (all IC50s>100 μM). MBCQ dilates coronary arteries via specific inhibition of cGMP-PDE.
|
-
- HY-N10663
-
-
- HY-145552
-
|
Azilsartan mepixetil
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Azilsartan mepixetil is the antagonist of angiotensin II receptor. Azilsartan mepixetil has stronger and longer blood pressure effect, more abvious and longer lasting heart rate lowering effect and high safety. Azilsartan mepixetil achieves ideal protective effect for heart and kidney functions. Azilsartan mepixetil has the potential for the research of hypertension, chronic heart failure and diabetic nephropathy (extracted from patent CN107400122A).
|
-
- HY-N2484
-
|
Methylnissolin
Astrapterocarpan
|
PDGFR
ERK
|
Cardiovascular Disease
|
|
Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10 μM. Methylnissolin inhibits PDGF-BB-induced phosphorylation of extracellular signal-regulated kinase 1/2 (ERIC1/2) mitogen-activated protein (MAP) kinase. Methylnissolin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation by inhibition of the ERK1/2 MAP kinase cascade.
|
-
- HY-17352
-
|
Clazosentan
Ro 61-1790; VML 588; AXV-034343
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
Clazosentan (Ro 61-1790) is a selective endothelin A (ETA) receptor antagonist. Clazosentan inhibits ET-1-mediated vasoconstriction. Clazosentan prevents cerebral vasospasm, vasospasm-related cerebral infarction.
|
-
- HY-P3138
-
|
(Sar1)-Angiotensin II
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
(Sar1)-Angiotensin II, an analogue of Angiotensin II, is a specific agonist of angiotensin AT1 receptor. (Sar1)-Angiotensin II binds to brain membrane-rich particles, with a Kd of 2.7 nM. (Sar1)-Angiotensin II can stimulate protein synthesis and cell growth in embryonic chick myocytes.
|
-
- HY-113673
-
|
A-935142
|
Potassium Channel
|
Cardiovascular Disease
|
|
A-935142 is a human ether-a-go-go-related gene (hERG, Kv 11.1) channel activator. A-935142 enhances hERG current in a complex manner by facilitation of activation, reduction of inactivation, and slowing of deactivation, and abbreviates atrial and ventricular repolarization.
|
-
- HY-P3919
-
|
Adrenotensin (human)
Pro-ADM-153-185 (human)
|
CGRP Receptor
|
Cardiovascular Disease
|
|
Adrenotensin (human) (Pro-ADM-153-185 (human)) is a 153-185 fragment of precursor peptide of Adrenomedullin. Adrenomedullin (ADM) is a 52-amino acid multifunctional peptide, which belongs to the CGRP superfamily of vasoactive peptide hormones.
|
-
- HY-U00309
-
-
- HY-108322
-
-
- HY-13817
-
-
- HY-17404
-
-
- HY-106471
-
|
Pildralazine
Propyldazine
|
Others
|
Cardiovascular Disease
|
|
Pildralazine (Propyldazine) is a hydralazinelike antihypertensive vasodilator containing a free hydrazine group. Pildralazine is orally active, has no significant carcinogenicity in mice model.
|
-
- HY-P3424
-
-
- HY-100750
-
-
- HY-134216
-
-
- HY-14181
-
-
- HY-102054
-
-
- HY-10274S
-
-
- HY-Y1620S
-
|
3-(3,4-Dimethoxyphenyl)propanoic acid-d10
|
Isotope-Labeled Compounds
|
Cardiovascular Disease
|
|
3-(3,4-Dimethoxyphenyl)propanoic acid-d10 is the deuterium labeled 3-(3,4-Dimethoxyphenyl)propanoic acid. 3-(3,4-Dimethoxyphenyl)propanoic acid is an orally active short-chain fatty acids (SCFAs). 3-(3,4-Dimethoxyphenyl)propanoic acid stimulates γ globin gene expression, erythropoiesis in vivo and is used for the β hemoglobinopathies and other anemias[1].
|
-
- HY-50768
-
-
- HY-18763S
-
|
Indobufen-d5
Ibustrin-d5
|
COX
|
Cardiovascular Disease
|
|
Indobufen-d5 is deuterium labeled Indobufen. Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1].
|
-
- HY-146332
-
|
Collagen-IN-1
|
Others
|
Cardiovascular Disease
|
|
Collagen-IN-1 (compound 3), an ortho-carbonyl hydroquinone derivative, is a selective inhibitor on collagen. Collagen-IN-1 inhibits agonist-induced platelet aggregation in a non-competitive manner with an IC50 value of 1.77 μM. Collagen-IN-1 reduces the expression of P-selectin, activation of glycoprotein IIb/IIIa, and release of adenosine triphosphate and CD63 from platelet. Collagen-IN-1 has the potential for platelet-related thrombosis diseases research.
|
-
- HY-10269
-
|
LY-517717
|
Factor Xa
|
Cardiovascular Disease
|
|
LY-517717 is a potent and orally active FXa inhibitor. LY-517717 shows antithrombotic and anticoagulant activity. LY-517717 has the potential for the research of venous thromboembolism after hip or knee replacement.
|
-
- HY-18681
-
|
Voxelotor
GBT 440
|
Others
|
Cardiovascular Disease
|
|
Voxelotor (GBT 440) is a potent inhibitor of haemoglobin S (HbS) polymerization. Voxelotor has the potential for sickle cell disease (SCD) treatment.
|
-
- HY-P99794
-
|
Osocimab
BAY 1213790
|
Factor Xa
|
Cardiovascular Disease
|
|
Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects.
|
-
- HY-10309
-
|
Sibrafiban
RO 48-3657
|
Integrin
|
Cardiovascular Disease
|
|
Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation.
|
-
- HY-147354
-
|
TriGalNAc CBz
|
LYTACs
|
Cardiovascular Disease
|
TriGalNAc CBz is a GalNAc derivative and tri-GalNAc is an asialoglycoprotein receptor (ASGPR) ligand. TriGalNAc CBz can be used for mRNA drug delivery as well as lysosomal targeted chimerism (LYTAC) studies.
|
-
- HY-N2237
-
-
- HY-90009S
-
|
Tadalafil-d3
IC-351-d3
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Tadalafil-d3 is the deuterium labeled Nortadalafil. Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.
|
-
- HY-N3216
-
-
- HY-14233
-
-
- HY-110390
-
-
- HY-116023
-
-
- HY-15472
-
-
- HY-N2282
-
-
- HY-N4309
-
|
Lotusine
|
Others
|
Cardiovascular Disease
|
|
Lotusine is a pure alkaloid extracted from the green seed embryo of Nelumbo nucifera Gaertn. Lotusine shows effects on the action potentials in myocardium and slow inward current in cardiac Purkinje fibers.
|
-
- HY-76652
-
-
- HY-B0997
-
|
Hydroquinidine
Dihydroquinidine; (+)-Hydroquinidine; Hydroconquinine
|
Others
|
Cardiovascular Disease
|
|
Hydroquinidine (Dihydroquinidine) is a derivative of Quinidine (an antiarrhythmic agent). Hydroquinidine prolongs the QT interval and has antiarrhythmic efficacy.
|
-
- HY-B0224
-
-
- HY-N3513
-
|
Mulberrin
Kuwanon C
|
Others
|
Cardiovascular Disease
|
|
Mulberrin is a strong inhibitor of organic anion-transporting polypeptide 2B1 (OATP2B1)-mediated estrone-3-sulfate (E3S) uptake with an IC50 value being 1.8 ±1.5 μM.
|
-
- HY-108351
-
|
IM-54
|
Necroptosis
|
Cardiovascular Disease
|
|
IM-54 is a selective inhibitor of oxidative stress-induced necrosis. IM-54 shows potent inhibitory activity against H2O2-induced necrosis. IM-54 acts as a potential cardioprotective agent and biological tool for investigating the molecular mechanisms of cell death.
|
-
- HY-W013989
-
-
- HY-N4266
-
|
Vinaginsenoside R8
|
Others
|
Cardiovascular Disease
|
|
Vinaginsenoside R8, a triterpenoid glycoside isolated from the rhizomes of Panacis majoris. Vinaginsenoside R8 displays activities against adenosine diphosphate (ADP)-induced platelet aggregation (IC50=25.18 μM).
|
-
- HY-109039
-
|
Praliciguat
IW-1973
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase stimulator, enhances NO signaling, acts as a vasodilator. Praliciguat (IW-1973) stimulates sGC in HEK-293 cells with an EC50 of 197 nM.
|
-
- HY-N2638
-
|
Ilexsaponin A
|
Apoptosis
|
Cardiovascular Disease
|
|
Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes.
|
-
- HY-U00208
-
-
- HY-12502B
-
-
- HY-B1696
-
|
Methyldopate
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Methyldopate is an ethyl ester proagent of α-Methyldopa (α-MD; HY-B0225). Methyldopa (L-(-)-α-Methyldopa) is an α-adrenergic agonist (selective for α2-adrenergic receptors). Methyldopate has the potential for severe hypertension research .
|
-
- HY-139400
-
|
FTX-6058
|
Histone Methyltransferase
|
Cardiovascular Disease
|
|
FTX-6058 is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). FTX-6058 can induce HbF protein expression in cell and murine models. FTX-6058 can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia.
|
-
- HY-120083
-
-
- HY-15574
-
-
- HY-100298
-
-
- HY-N0684S3
-
-
- HY-100160
-
-
- HY-10163
-
|
Dabigatran
BIBR 953; BIBR 953ZW
|
Thrombin
|
Cardiovascular Disease
|
|
Dabigatran (BIBR 953), an oral anticoagulant, is a reversible, potent, competitive direct thrombin inhibitor (Ki=4.5 nM). Dabigatran (BIBR 953) also inhibits thrombin-induced platelet aggregation (IC50=10 nM).
|
-
- HY-77521
-
-
- HY-W015007
-
|
Metyrosine
|
COX
|
Cardiovascular Disease
|
|
Metyrosine is a selective tyrosine hydroxylase enzyme inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity. Metyrosine is a very effective agent for blood pressure control.
|
-
- HY-108495
-
|
CYM50308
ML248
|
LPL Receptor
|
Cardiovascular Disease
|
|
CYM50308 (ML248) is a potent, selective and high affinity sphingosine-1-phosphate receptor 4 (S1P4-R) agonist with an EC50 of 56 nM. CYM50308 displays 37-fold more selective for S1P4-R than S1P5-R. CYM50308 has no activity at S1P1-R, S1P2-R and S1P3-R subtypes at concentrations up to 25 μM.
|
-
- HY-P4420
-
-
- HY-101054
-
-
- HY-108544
-
-
- HY-B0204A
-
-
- HY-B0375
-
-
- HY-109592
-
-
- HY-144439
-
|
HTS07545
|
Others
|
Cardiovascular Disease
|
|
HTS07545 is a potent sulfide:quinone oxidoreductase (SQOR) inhibitor with an IC50 of 30 nM. HTS07545 decrease the rate of breakdown of hydrogen sulfide (H2S). HTS07545 can be used for heart failure research.
|
-
- HY-147503
-
|
Vin-F03
|
Apoptosis
|
Cardiovascular Disease
|
|
Vin-F03 is a potent pancreatic β-cells protective agent with an EC50 of 0.27 µM. Vin-F03 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-F03 can be used for type 2 diabetes mellitus research.
|
-
- HY-111536
-
-
- HY-16403
-
|
Polythiazide
|
Others
|
Cardiovascular Disease
|
|
Polythiazide is a potent and orally active thiazide diuretic agent that has antihypertensive effect. Polythiazide can decrease edema and decrease blood pressure. Polythiazide also has phototoxicity.
|
-
- HY-125639
-
|
AR-13503
|
PKC
ROCK
|
Cardiovascular Disease
|
|
AR-13503 a ROCK/PKC inhibitor, inhibiting angiogenesis and enhancing retinal pigment epithelium (RPE) permeability. AR-13503 also inhibits the formation of aberrant neovascularization (NV) in oxygen-induced retinopathy (OIR) model in mice.
|
-
- HY-B1582A
-
-
- HY-14254
-
|
Olprinone Hydrochloride
Loprinone Hydrochloride
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Olprinone (Loprinone) Hydrochloride is a potent phosphodiesterase (PDE) 3 inhibitor, with IC50s of 150, 100, 0.35 and 14 μM for PDE1, PDE2, PDE3 and PDE4, respectively. Olprinone Hydrochloride is used for the research of heart failure due to its positive inotropic and vasodilative effects. Anti-inflammatory activity.
|
-
- HY-108591
-
|
L-364,373
R-L3
|
Potassium Channel
|
Cardiovascular Disease
|
|
L-364,373 (R-L3) is a voltage-gated Kv7.1 (KCNQ1)/mink channels activator. L-364,373 activates Iks (slow delayed rectifier potassium current) and shortens action potential duration in guinea pig cardiac myocytes, and suppresses early afterdepolarizations in rabbit ventricular myocytes.
|
-
- HY-13422
-
|
Zatebradine hydrochloride
UL-FS-49; UL-FS-49CL
|
HCN Channel
|
Cardiovascular Disease
|
|
Zatebradine (UL-FS-49 (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 values 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively.
|
-
- HY-B0592
-
|
Trandolapril
RU44570
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI).
|
-
- HY-122915
-
-
- HY-N0666A
-
-
- HY-101109
-
-
- HY-W050000
-
-
- HY-P9951A
-
|
Ranibizumab (anti-VEGF)
RG-6321 (anti-VEGF)
|
VEGFR
|
Cardiovascular Disease
|
|
Ranibizumab (RG-6321) (anti-VEGF) is a humanized anti-VEGF monoclonal antibody fragment and can recognize all VEGF-A isoforms (VEGF110, VEGF121, and VEGF165). Ranibizumab (anti-VEGF) slows vision loss in vivo and is used for wet age-related macular degeneration (AMD) research.
|
-
- HY-112264
-
-
- HY-100554
-
|
BMY 7378
|
Adrenergic Receptor
5-HT Receptor
|
Cardiovascular Disease
|
|
BMY 7378 is a selective antagonist of α1D-adrenoceptor (α1D-AR). BMY 7378 binds to membranes expressing the cloned rat α1D-AR with a >100-fold higher affinity (Ki=2 nM) than binding to either the cloned rat α1A-AR (Ki=800 nM) or the hamster α1B-AR (Ki=600 nM). BMY 7378 is a 5-HT1A receptor partial agonist.
|
-
- HY-N1982
-
|
Denudatine
|
Others
|
Cardiovascular Disease
|
|
Denudatine, is primarily isolated from plants of the genera Aconitum and Delphinium. Denudatine has effects on action potential of ventricular fibers and inhibits arrhythmogenic action of aconitine.
|
-
- HY-101124
-
-
- HY-117970
-
|
MMPI-1154
|
MMP
|
Cardiovascular Disease
|
|
MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) MMP-2 inhibitor(IC50=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC50s of 1.8 μM,10 μM, and 13 μM, respectively.
|
-
- HY-148129
-
|
TRPC6-IN-3
|
TRP Channel
|
Cardiovascular Disease
|
|
TRPC6-IN-3 (compound 17) is a potent, orally active transient receptor potential C6 ion channel (TRPC6) inhibitor. TRPC6-IN-3 modulates not only intracellular calcium concentration, but also membrane potential by modulating the flux of cations including calcium and sodium ions. TRPC6-IN-3 can be used in research of respiratory system.
|
-
- HY-A0144
-
-
- HY-12773AS
-
-
- HY-135774
-
|
6-Hydroxybenzbromarone
|
Drug Metabolite
Phosphatase
|
Cardiovascular Disease
|
|
6-Hydroxybenzbromarone is the major metabolite of Benzbromarone with a longer half-life and greater pharmacological potency than the parent compound. 6-Hydroxybenzbromarone is a protein Eyes Absent 3 (EYA3) inhibitor with an IC50 value of 21.5 μM. 6-Hydroxybenzbromarone is an angiogenic agent, has strong inhibitory effects on cell migration, tubulogenesis, and angiogenic sprouting.
|
-
- HY-103316
-
|
trans-Ned 19
|
Calcium Channel
|
Cardiovascular Disease
|
|
trans-Ned 19, a NAADP antagonist and TPC blocker, suppresses the calcium signal in human umbilical vein endothelial cells (HUVEC) and the rat aorta relaxation in response to low histamine concentrations.
|
-
- HY-14284S
-
-
- HY-107354
-
|
Gepefrine
|
Others
|
Cardiovascular Disease
|
|
Gepefrine is an orally active pressor agent and sympathomimetic agent. Gepefrine improves the early orthostatic disregulation of the arterial pressure.
|
-
- HY-101308
-
|
MRS2179 tetrasodium
|
P2Y Receptor
|
Cardiovascular Disease
|
|
MRS2179 tetrasodium is a competitive P2Y1 receptor antagonist, with a Kb of 102 nM and a pA2 of 6.99 for turkey P2Y1 receptor. MRS2179 tetrasodium is selective for P2Y1 over P2X1 (IC50=1.15 µM), P2X3 (12.9 µM), P2X2, P2X4, P2Y2, P2Y4, and P2Y6 receptors. MRS2179 tetrasodium inhibits platelet aggregation.
|
-
- HY-N9380
-
-
- HY-106720
-
|
Amosulalol
YM 09538
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Amosulalol (YM 09538) is an orally active and dual inhibitor of α1/β1-Adrenergic Receptor. Amosulalol exhibits antihypertensive activity via α1-Adrenergic Receptor inhibition. Amosulalol decreases reflexogenic increases in heart rate and plasma renin activity (PRA) via β1-Adrenergic Receptor inhibition in spontaneously hypertensive rats (SHR).
|
-
- HY-142019
-
|
Tanshinol borneol ester
|
Akt
AMPK
|
Cardiovascular Disease
|
|
Tanshinol borneol ester, an angiogenesis stimulator, promoted multiple key steps of angiogenesis through Akt and MAPK signalling pathways. Tanshinol borneol ester has anti-ischemic and anti-atherosclerosis activities.
|
-
- HY-B0686
-
-
- HY-153392
-
|
TYA-018
|
HDAC
|
Cardiovascular Disease
|
|
TYA-018 is an orally active, potent and highly selective HDAC6 inhibitor. TYA-018 can protect heart function in mice. TYA-018 also enhances energetics in mice by increasing expression of targets associated with fatty acid metabolism, protein metabolism, and oxidative phosphorylation.
|
-
- HY-107335
-
|
Aplodan
Creatinol O-phosphate; Creatinol phosphate; Creatinolfosfate
|
Others
|
Cardiovascular Disease
|
|
Aplodan is an antiischemic and antiarrhythmic agent. Aplodan has a protective action on cell membrane. Aplodan has the potential for the research of ischemic heart or ischemic heart disease with persistent ventricular premature beats (VPB) .
|
-
- HY-N2299
-
|
Morusinol
|
Others
|
Cardiovascular Disease
|
|
Morusinol is a flavonoid isolated from Morus alba root bark. Morusinol has an antiplatelet activity and significantly inhibits arterial thrombosis in vivo.
|
-
- HY-101649
-
-
- HY-U00378
-
-
- HY-B0804
-
|
Nadolol
SQ-11725
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research.
|
-
- HY-P1519B
-
-
- HY-139727A
-
|
S(-)-Bisoprolol fumarate
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
S(-)-Bisoprolol fumarate is a S(-)-enantiomer of Bisoprolol fumarate. Bisoprolol fumarate is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
|
-
- HY-103193
-
|
NKH477
Colforsin dapropate hydrochloride
|
Adenylate Cyclase
|
Cardiovascular Disease
|
|
NKH477 (Colforsin dapropate hydrochloride) directly activates the catalytic unit of adenylate cyclase and increases intracellular cAMP. NKH477 is a forskolin derivative that improves cardiac failure mainly through its beneficial effects on diastolic cardiac function. NKH477 exerts an antiproliferative effect in vivo with an altered cytokine profile to inhibit the acute rejection of rat orthotopic lung allografts.
|
-
- HY-P0318
-
-
- HY-B0093
-
-
- HY-B1433
-
-
- HY-Z0075
-
-
- HY-P1839
-
|
Angiotensin I/II (1-5)
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Angiotensin I/II 1-5 is a peptide that contains the amino acids 1-5, which is converted from Angiotensin I/II. Angiotensin I is formed by the action of renin on angiotensinogen. Angiotensin II is produced from angiotensin I. Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.
|
-
- HY-A0021S
-
-
- HY-150790
-
-
- HY-19614
-
|
BMS-795311
|
CETP
|
Cardiovascular Disease
|
|
BMS-795311 is a potent and orally bioavailable inhibitor of cholesteryl ester transfer protein (CETP), with IC50s of 4 nM in an enzyme-based scintillation proximity assay (SPA) and 0.22 μM in a human whole plasma assay (hWPA), respectively.
|
-
- HY-17500
-
|
Ataciguat
HMR-1766
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
Ataciguat (HMR-1766) is a nitric oxide-independent soluble guanylate cyclase (sGC) activator. Ataciguat is able to activate the ferric heme-iron redox form of sGC that stimulate the production of cyclic GMP (cGMP). Ataciguat exhibits vasodilator effects.
|
-
- HY-N7607
-
-
- HY-10304
-
-
- HY-112627
-
-
- HY-B0612E
-
-
- HY-129029S
-
|
Bisoprolol-d5
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Bisoprolol-d5 is the deuterium labeled Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research[1][2].
|
-
- HY-B0387A
-
|
Ibutilide
U70226E free base
|
Potassium Channel
|
Cardiovascular Disease
|
|
Ibutilide (U70226E free base), an action potential-prolonging antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K + current (IKr) in AT-1 cells.
|
-
- HY-101404A
-
-
- HY-147256
-
-
- HY-B1587
-
-
- HY-12531
-
|
Encainide hydrochloride
MJ9067 hydrochloride
|
Others
|
Cardiovascular Disease
|
|
Encainide (MJ9067) hydrochloride is an antiarrhythmic agent with class IC activity. Encainide has the potential for life-threatening ventricular arrhythmias, symptomatic ventricular arrhythmias and supraventricular arrhythmias research.
|
-
- HY-17004S1
-
-
- HY-108457
-
|
9-Phenanthrol
9-Hydroxyphenanthrene; NSC 50554
|
TRP Channel
|
Cardiovascular Disease
|
|
9-Phenanthrol (9-Hydroxyphenanthrene) is a potent and selective human TRPM4 inhibitor, with an IC50 of 20 μM. 9-Phenanthrol can be used for the research of ischemia-reperfusion injury.
|
-
- HY-N2929
-
-
- HY-14667
-
|
Lomitapide
AEGR-733; BMS-201038
|
Others
|
Cardiovascular Disease
|
|
Lomitapide (AEGR-733; BMS-201038) is a potent inhibitor of microsomal triglyceride-transfer protein (MTP) with an IC50 of 8 nM in vitro.
|
-
- HY-N1974
-
-
- HY-U00383
-
-
- HY-N10762
-
-
- HY-119695AS
-
|
Simvastatin acid-d6 ammonium
Tenivastatin-d6 (ammonium)
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Simvastatin acid-d6 (ammonium)mis the deuterium labeled Simvastatin acid ammonium. Simvastatin ammonium is an active metabolite of simvastatin lactone mediated by CYP3A4/5 in the intestinal wall and liver (pKa=5.5). Simvastatin ammonium reduces indoxyl sulfate-mediated reactive oxygen species and modulates OATP3A1 expression in cardiomyocytes and HEK293 cells transfected with the OATP3A1 gene[1].
|
-
- HY-118543
-
|
TM6089
|
HIF/HIF Prolyl-Hydroxylase
|
Cardiovascular Disease
|
|
TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector.
|
-
- HY-U00274
-
-
- HY-18206A
-
-
- HY-100471
-
-
- HY-120034
-
-
- HY-109190
-
|
Seralutinib
GB002; PK10571
|
PDGFR
|
Cardiovascular Disease
|
|
Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib (GB002) is used in the study for pulmonary arterial hypertension.
|
-
- HY-B1109
-
-
- HY-10627
-
|
GW3965
|
LXR
|
Cardiovascular Disease
|
|
GW3965 is a potent, selective liver X receptor (LXR) agonist with EC50s of 190 nM and 30 nM for hLXRα and hLXRβ, respectively.
|
-
- HY-145553
-
-
- HY-N6243
-
-
- HY-101274
-
-
- HY-101312
-
-
- HY-145284
-
|
APJ receptor agonist 4
|
Apelin Receptor (APJ)
|
Cardiovascular Disease
|
|
APJ receptor agonist 4 is a potent and orally active agonist of apelin receptor (APJ) with EC50 and Ki of 0.06 nM and 0.07 nM respectively. APJ receptor agonist 4 displays excellent pharmacokinetic profiles in the rodent heart failure (HF) model. APJ receptor agonist 4 also shows an acceptable safety profile in preclinical toxicology studies. APJ receptor agonist 4 leads to improved cardiac function and can be used for researching the HF disease.
|
-
- HY-N3460
-
-
- HY-101408
-
-
- HY-P4560
-
|
H-Pro-Phe-OH
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
H-Pro-Phe-OH is a dipeptide containing proline and phenylalanine, which can serve as a substrate for prolinase. H-Pro-Phe-OH can also be used for polypeptide synthesis, where phenylalanine is an aromatic amino acid that can inhibit the activity of Angiotensin-converting enzyme (ACE, HY-P2983).
|
-
- HY-N3668
-
|
Cyclomorusin
Cyclomorusin A; Cyclomulberrochromene
|
Others
|
Cardiovascular Disease
|
|
Cyclomorusin (Cyclomorusin A; Cyclomulberrochromene) is a prenylflavonoid with antiplatelet activity. Cyclomorusin also inhibits markedly collagen-induced platelet aggregation.
|
-
- HY-19736
-
-
- HY-50903S
-
|
Rivaroxaban-d4
BAY 59-7939-d4
|
Factor Xa
|
Cardiovascular Disease
|
|
Rivaroxaban-d4 is a deuterium labeled Rivaroxaban. Rivaroxaban is a highly potent，selective and direct Factor Xa (FXa) inhibitor, achieving a strong gain in anti-FXa potency (IC50 0.7 nM; Ki 0.4 nM)[1][2].
|
-
- HY-78847
-
-
- HY-113898
-
-
- HY-I0400
-
-
- HY-106450
-
|
Binodenoson
MRE-0470; WRC 0470
|
Adenosine Receptor
|
Cardiovascular Disease
|
|
Binodenoson (MRE-0470) is a potent and selective A2A adenosine receptor agonist (KD=270 nM). Binodenoson is being developed as a short-acting coronary vasodilator as an adjunct to radiotracers for use in myocardial stress imaging.
|
-
- HY-N0518
-
|
Toddalolactone
|
PAI-1
|
Cardiovascular Disease
|
|
Toddalolactone, a main component of Toddalia asiatica, inhibits the activity of recombinant human plasminogen activator inhibitor-1 (PAI-1), with an IC50 value of 37.31 μM.
|
-
- HY-14184S
-
|
Macitentan-d4
ACT-064992-d4
|
Endothelin Receptor
Apoptosis
|
Cardiovascular Disease
|
|
Macitentan-d4 is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH)[1].
|
-
- HY-A0116A
-
-
- HY-105064D
-
|
Zoniporide hydrochloride hydrate
CP-597396 hydrochloride hydrate
|
Na+/H+ Exchanger (NHE)
|
Cardiovascular Disease
|
|
Zoniporide (CP-597396) hydrochloride hydrate is a potent and selective inhibitor of sodium-hydrogen exchanger type 1 (NHE-1). Zoniporide hydrochloride hydrate inhibits human NHE-1 (IC50=14 nM), and has >150-fold selectivity versus other NHE isoforms. Zoniporide hydrochloride hydrate potently inhibits ex vivo NHE-1-dependent swelling of human platelets (IC50=59 nM).
|
-
- HY-114086
-
|
ML359
|
PDI
|
Cardiovascular Disease
|
|
ML359 is a potent, selctive and reversible inhibitor of protein disulfide isomerase (PDI), with an IC50 of 250 nM. ML359 can prevent thrombus formation in vivo.
|
-
- HY-W042039
-
-
- HY-N5057
-
|
Przewalskinic acid A
|
Others
|
Cardiovascular Disease
|
|
Przewalskinic acid A is a phenolic acid found in the Salvia przewalskii Maxim herb. Phenolic acids show potent antioxidant activities and potential effects in protecting against brain and heart damage caused by ischemia reperfusion.
|
-
- HY-139998
-
-
- HY-101069
-
-
- HY-B0753
-
-
- HY-119442
-
|
Quininib
|
Leukotriene Receptor
|
Cardiovascular Disease
|
|
Quininib is a cysteinyl leukotriene 1 and 2 receptor antagonist with IC50s of 1.2 and 52 μM for CysLT1R and CysLT2R, respectively. Quininib is a potent inhibitor of developmental angiogenesis in the zebrafish eye. Quininib can be used for the research of ocular neovascular pathologies and may complement current anti-VEGF biological agents.
|
-
- HY-142620
-
-
- HY-144549
-
|
LXR agonist 1
|
LXR
|
Cardiovascular Disease
|
|
LXR (Liver X receptor) agonist 1 is potent LXR agonist with AC50s of 1.5 nM and 12 nM for LXR-α and LXR-β, respectively. LXR agonist 1 has the potential for the research of atherosclerosis.
|
-
- HY-122560A
-
|
VU0134992 hydrochloride
|
Potassium Channel
|
Cardiovascular Disease
|
|
VU0134992 hydrochloride is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 hydrochloride is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV.
|
-
- HY-15284B
-
|
Prasugrel (Maleic acid)
PCR 4099 (Maleic acid)
|
P2Y Receptor
|
Cardiovascular Disease
|
|
Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation.
|
-
- HY-12502
-
-
- HY-101628
-
-
- HY-P0143
-
-
- HY-15847
-
|
HS38
|
DAPK
|
Cardiovascular Disease
|
|
HS38 is a potent, selective, and ATP-competitive inhibitor of death-associated protein kinase 1 (DAPK1) and zipper-interacting protein kinase (ZIPK, also called DAPK3), with Kds of 300 nM and 280 nM, respectively. HS38 is also a PIM3 inhibitor with an IC50 of 200 nM. HS38 can be used for the research of smooth muscle related disorders.
|
-
- HY-122543A
-
-
- HY-B1654
-
-
- HY-W010950
-
|
Flecainide
|
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide is a potent and orally active antiarrhythmic agent. Flecainide blocks the cardiac fast inward Na + current (INa) and the rapid component of the delayed rectifier K + current. Flecainide prolongs the action potential duration (APD) in ventricular and atrial muscle fibres. Flecainide has the potential for the research of fetal tachycardias.
|
-
- HY-B1191
-
-
- HY-P3624
-
|
Cenderitide
|
Guanylate Cyclase
|
Cardiovascular Disease
|
|
Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research.
|
-
- HY-139727
-
|
S(-)-Bisoprolol
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
S(-)-Bisoprolol is a S(-)-enantiomer of Bisoprolol. Bisoprolol is a potent, selective and orally active β1-adrenergic receptor blocker. Bisoprolol has little activity on β2-receptor and has the potential for hypertension, coronary artery disease and stable ventricular dysfunction research.
|
-
- HY-W015007S
-
|
Metyrosine-13C9,15N,d7
|
COX
|
Cardiovascular Disease
|
|
Metyrosine- 13C9, 15N,d7 is the deuterium, 13C-, and 15-labeled Metyrosine. Metyrosine is a selective tyrosine hydroxylase enzyme inhibitor. Metyrosine exerts anti-inflammatory and anti-ulcerative effects. Metyrosine significantly inhibits high COX-2 activity[1]. Metyrosine is a very effective agent for blood pressure control[2].
|
-
- HY-14304A
-
|
Zinterol hydrochloride
MJ 9184 hydrochloride
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Zinterol hydrochloride (MJ 9184 hydrochloride) is a potent and selective β2-adrenoceptor agonist. Zinterol hydrochloride increases ICa in a concentration-dependent manner with an EC50 of 2.2 nM. Zinterol hydrochloride induces ventricular arrhythmias in conscious heart failure rabbits.
|
-
- HY-135381
-
-
- HY-147502
-
|
Vin-C01
|
Apoptosis
|
Cardiovascular Disease
|
|
Vin-C01 is a potent pancreatic β-cells protective agent with an EC50 of 0.22 µM. Vin-C01 effectively promotes β-cell survival and protects β-cells from STZ-induced apoptosis. Vin-C01 can be used for type 2 diabetes mellitus research.
|
-
- HY-119608
-
|
GSK854
|
Others
|
Cardiovascular Disease
|
|
GSK854 is a potent Inhibitor of Troponin I-Interacting Kinase (TNNI3K). GSK854 is a suitable lead for identifying new cardiac medicines and have been employed as in vivo tools in investigational studies aimed at defining the role of TNNI3K within heart failure.
|
-
- HY-19765
-
|
GSK2798745
|
TRP Channel
|
Cardiovascular Disease
|
|
GSK2798745 is a potent, selective, and orally active transient receptor potential vanilloid 4 (TRPV4) ion channel blocker with IC50s of 1.8 and 1.6 nM for hTRPV4 and rTRPV4, respectively. GSK2798745 can be used in cardiac and respiratory diseases research.
|
-
- HY-123068
-
-
- HY-Y1620
-
-
- HY-90009
-
|
Nortadalafil
Demethyl Tadalafil
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Nortadalafil is demethyl Tadalafil, which is a PDE5 inhibitor, currently marketed in pill form for treating erectile dysfunction (ED) under the name Cialis; and under the name Adcirca for the treatment of pulmonary arterial hypertension.
|
-
- HY-103346
-
|
MMPSI
|
Caspase
Apoptosis
|
Cardiovascular Disease
|
|
MMPSI is a potent and selective small molecule caspase 3 and caspase 7 inhibitor with an IC50 of 1.7 μM for human caspase-3. MMPSI can significantly reduce ischemia-reperfusion-induced infarct size in the isolated rabbit heart, and reduce apoptosis in both the ischemic myocardium and isolated cardiomyocytes. MMPSI can be used for researching cardioprotection.
|
-
- HY-N10198
-
-
- HY-N0553
-
-
- HY-B0387
-
-
- HY-105647
-
|
Ambuphylline
Bufylline
|
Phosphodiesterase (PDE)
|
Cardiovascular Disease
|
|
Ambuphylline (Bufylline) is a bronchodilator. Ambuphylline is a theophylline derivative possibly acting through phosphodiesterase inhibition. Ambuphylline can be used for the research of asthma and other lung diseases.
|
-
- HY-149922
-
-
- HY-17402S1
-
-
- HY-N0660
-
-
- HY-17497
-
-
- HY-16738A
-
|
Eleclazine hydrochloride
GS 6615 hydrochloride
|
Sodium Channel
Potassium Channel
|
Cardiovascular Disease
|
|
Eleclazine (GS 6615) hydrochloride is a selective cardiac late sodium current inhibitor and a weak inhibitor of potassium current with IC50 value of <1 μM and approximately 14.2 μM, respectively. Eleclazine hydrochloride shows concurrent protection against autonomically induced atrial premature beats, repolarization alternans and heterogeneity, and atrial fibrillation in porcine model. Eleclazine hydrochloride can be used to research cardiac arrhythmias.
|
-
- HY-10758
-
|
FXa-IN-1
|
Factor Xa
|
Cardiovascular Disease
|
|
FXa-IN-1 is a FXa inhibitor (IC50: 3 nM, Ki: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders.
|
-
- HY-152086
-
|
DRP1i27
|
Dynamin
|
Cardiovascular Disease
|
|
DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury.
|
-
- HY-B0165CS
-
-
- HY-N5037
-
|
Ilexoside D
|
Others
|
Cardiovascular Disease
|
|
Ilexoside D is isolated from the roots of Ilex pubescens Hook. et Arn. Ilexoside D has the anti-tissue factor activity as well as the antithrombotic activity.
|
-
- HY-N3670
-
|
Cycloolivil
Isoolivil
|
Others
|
Cardiovascular Disease
|
|
Cycloolivil (Isoolivil) is a natural polyphenolic compound with a significant radical scavenging activity. Antioxidant and Antiaggregant effects.
|
-
- HY-W012159
-
|
Methionylserine
H-MET-SER-OH
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Methionylserine (H-MET-SER-OH) is a methionine- and serine-containing dipeptide. Methionylserine binds to and translocation via intestinal di/tri-peptide transporter 1 (hPEPT1) with a Km value of 0.2 mM. Methionylserine inhibits ACE enzyme activity. Methionylserine can be used in the research of hypension.
|
-
- HY-148037
-
-
- HY-B0782S
-
-
- HY-150039
-
-
- HY-U00186
-
-
- HY-P0316A
-
|
TP508 TFA
|
Thrombin
NO Synthase
|
Cardiovascular Disease
|
|
TP508 TFA is a 23-amino acid nonproteolytic thrombin peptide that represents a portion of the receptor-binding domain of thrombin molecule. TP508 TFA activates endothelial NO synthase (eNOS) and stimulates production of NO in human endothelial cells. TP508 TFA activates endothelial cells and stem cells to revascularize and regenerate tissues.
|
-
- HY-B0432AS3
-
-
- HY-N3164
-
-
- HY-106688A
-
-
- HY-139293
-
|
PF-07059013
|
Others
|
Cardiovascular Disease
|
|
PF-07059013 is an orally active and potent noncovalent modulator of sickled hemoglobin (HbS). PF-07059013 specifically binds to Hb with nanomolar affinity and displays strong partitioning into red blood cells (RBCs). PF-07059013 can be used for sickle cell disease (SCD) research.
|
-
- HY-U00149
-
-
- HY-106446
-
-
- HY-B1107
-
|
Naftidrofuryl oxalate
Nafronyl oxalate salt
|
5-HT Receptor
|
Cardiovascular Disease
|
|
Naftidrofuryl oxalate (Nafronyl oxalate salt) is a drug used in the management of peripheral and cerebral vascular disorders as a vasodilator, enhance cellular oxidative capacity, and may also be a 5-HT2 receptor antagonist.
|
-
- HY-N3063
-
|
Pimaric acid
|
Others
|
Cardiovascular Disease
|
|
Pimaric acid is a resin acid that has been found in A. cordata and various pines. Pimaric acid reduces mRNA expression, protein levels, and promoter activity of matrix metalloproteinase-9 (MMP-9) in TNF-α-stimulated human aortic smooth muscle cells (HASMCs).
|
-
- HY-115420
-
-
- HY-131722
-
|
EA4
|
Phospholipase
|
Cardiovascular Disease
|
|
EA4, a derivative of quinone, is an inhibitor for both rPLA and cPLA. EA4 can inhibit rPLA2 with a Ki value of 130 μM. EA4 can be used for the research of hemostasis, thrombosis, and erythropoiesis.
|
-
- HY-N0666S10
-
-
- HY-150022
-
-
- HY-113317
-
-
- HY-14276
-
|
Gallopamil
Methoxyverapamil
|
Calcium Channel
|
Cardiovascular Disease
|
|
Gallopamil (Methoxyverapamil), a methoxy derivative of Verapamil, is a phenylalkylamine calcium antagonist. Gallopamil inhibits acid secretion in a concentration-dependent manner with an IC50 of 10.9 μM. Gallopamil is a potent antiarrhythmic and vasodilator agent.
|
-
- HY-147393
-
-
- HY-135328AS
-
|
Norverapamil-d7 hydrochloride
(±)-Norverapamil-d7 (hydrochloride); D591-d7 (hydrochloride)
|
Calcium Channel
|
Cardiovascular Disease
|
|
Norverapamil-d7 (hydrochloride) is a deuterium labeled Norverapamil. Norverapamil ((±)-Norverapamil), an N-demethylated metabolite of Verapamil, is a L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor[1][2].
|
-
- HY-10264C
-
|
Edoxaban hydrochloride
DU-176 hydrochloride
|
Factor Xa
Thrombin
|
Cardiovascular Disease
|
|
Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Ki values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research.
|
-
- HY-10787
-
|
Ximelagatran
H 376/95
|
Thrombin
|
Cardiovascular Disease
|
|
Ximelagatran (H 376/95) is an orally active thrombin inhibitor that selectively and competitively inhibits both free and clot-bound thrombin. Ximelagatran is an anticoagulant agent with a rapid onset of anticoagulant effect, predictable, dose-dependent pharmcokinetics and pharmacodynamics.
|
-
- HY-17429
-
|
Flecainide acetate
R-818
|
Sodium Channel
|
Cardiovascular Disease
|
|
Flecainide acetate (R-818) is a class 1C antiarrhythmic agent especially used for the management of supraventricular arrhythmia; works by blocking the Nav1.5 sodium channel in the heart, causing prolongation of the cardiac action potential.
|
-
- HY-B0153AS
-
-
- HY-100771
-
-
- HY-146173
-
-
- HY-D0816
-
|
Rhodamine 123
RH-123; R-22420
|
Fluorescent Dye
|
Cardiovascular Disease
|
|
Rhodamine dyes are membrane-permeable cationic fluorescent probes that specifically recognize mitochondrial membrane potentials, thereby attaching to mitochondria and producing bright fluorescence, and at certain concentrations, rhodamine dyes have low toxicity to cells, so they are commonly used to detect mitochondria in animal cells, plant cells, and microorganisms.
|
-
- HY-U00370
-
-
- HY-13104
-
-
- HY-152190
-
|
JB002
|
Myosin
|
Cardiovascular Disease
|
|
JB002 is a myosin II inhibitor, with an IC50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.
|
-
- HY-P99415
-
|
Abelacimab
MAA868
|
Factor Xa
|
Cardiovascular Disease
|
|
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies.
|
-
- HY-107396
-
|
YM-750
|
Acyltransferase
|
Cardiovascular Disease
|
|
YM-750 is a potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor (IC50=0.18 μM). ACAT catalyzes the formation of cholesteryl esters from cholesterol and long-chain fatty-acyl-coenzyme A.
|
-
- HY-B1362S
-
-
- HY-107997
-
-
- HY-103227
-
-
- HY-111013
-
|
VK-II-86
|
Others
|
Cardiovascular Disease
|
|
VK-II-86 is a Carvedilol (HY-B0006) analogue lacking antagonist activity at β-adrenoceptors, in hypokalaemia. VK-II-86 prevents hypokalaemia-induced ventricular arrhythmia through multi-channel effects. VK-II-86 prevents all hypokalaemia-induced changes in ion channel activity and oxidative stress.
|
-
- HY-I0400S2
-
-
- HY-118628
-
-
- HY-15407S
-
|
Sacubitril-d4
AHU-377-d4
|
Neprilysin
|
Cardiovascular Disease
|
|
Sacubitril-d4 is the deuterium labeled Sacubitril. Sacubitril (AHU-377) is a potent NEP inhibitor with an IC50 of 5 nM. Sacubitril (AHU-377) is a component of the heart failure medicine LCZ696.
|
-
- HY-B0231A
-
|
Enalaprilat
MK-422 anhydrous
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Enalaprilat (MK-422 anhydrous), the active metabolite of the oral proagent Enalapril, is a potent, competitive and long-acting angiotensin-converting enzyme (ACE) inhibitor, with an IC50 of 1.94 nM. Enalaprilat can be used for the research of hypertension.
|
-
- HY-U00175
-
-
- HY-N1155
-
-
- HY-108566
-
-
- HY-16104
-
-
- HY-B0368S
-
|
Captopril-d3
SQ 14225-d3
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM[1][2][3].
|
-
- HY-113121S
-
|
Vanillylmandelic acid-d3
|
Endogenous Metabolite
|
Cardiovascular Disease
|
|
Vanillylmandelic acid-d3 is the deuterium labeled Vanillylmandelic acid. Vanillylmandelic acid is the endproduct of epinephrine and norepinephrine metabolism. Vanillylmandelic acid can be used as an indication of the disorder in neurotransmitter metabolism as well. Vanillylmandelic acid has antioxidant activity towards DPPH radical with an IC50 value of 33 μM[1].
|
-
- HY-110273
-
-
- HY-50667
-
|
Apixaban
BMS-562247-01
|
Factor Xa
|
Cardiovascular Disease
|
|
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. Apixaban is in development for the prevention and treatment of various thromboembolic diseases.
|
-
- HY-18600AS
-
|
Azimilide-d8 dihydrochloride
NE-10064-dd8 (dihydrochloride)
|
Potassium Channel
|
Cardiovascular Disease
|
|
Azimilide-d8 (dihydrochloride) is the deuterium labeled Azimilide dihydrochloride. Azimilide Dihydrochloride (NE-10064 Dihydrochloride) is a class III antiarrhythmic compound, inhibits I(Ks) and I(Kr) in guinea-pig cardiac myocytes and I(Ks) (minK) channels expressed in Xenopus oocytes.
|
-
- HY-B0615A
-
|
Moricizine Hydrochloride
EN 313; Ethmosine; Ethmozin
|
Others
|
Cardiovascular Disease
|
|
Moricizine Hydrochloride (EN 313) is an orally active Class I antiarrhythmic agent. Moricizine Hydrochloride decreases the maximum rate of phase 0 depolarization; increases rates of phase 2 and 3 repolarization, decreases action potential duration, and decreases effective refractory period.
|
-
- HY-117743
-
|
Eprosartan
SKF-108566J free base
|
Angiotensin Receptor
|
Cardiovascular Disease
|
|
Eprosartan (SKF-108566J free base) is a selective, competitive, nonpeptid and orally active angiotensin II receptor antagonist, used as an antihypertensive. Eprosartan binds angiotensin II receptor with IC50s of 9.2 nM and 3.9 nM in rat and human adrenal cortical membranes, respectively .
|
-
- HY-152087
-
|
DCZ19931
|
ERK
p38 MAPK
|
Cardiovascular Disease
|
|
DCZ19931 is a potent multi-targeting kinase inhibitor. DCZ19931 has anti-angiogenic effects on ocular neovascularization. DCZ19931 also inhibits ERK1/2-MAPK and p38-MAPK signaling.
|
-
- HY-B0930
-
-
- HY-125112
-
-
- HY-147323
-
-
- HY-B0556
-
|
Tetrahydrozoline
Tetryzoline
|
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Tetrahydrozoline (Tetryzoline), a derivative of imidazoline, is an α-adrenergic agonist that causes vasoconstriction. Tetrahydrozoline is widely used for the research of nasal congestion and conjunctival congestion.
|
-
- HY-N2073
-
-
- HY-10268
-
|
Betrixaban
PRT054021
|
Factor Xa
|
Cardiovascular Disease
|
|
Betrixaban (PRT054021) is a highly potent, selective, and orally efficacious factor Xa (fXa) inhibitor with an IC50 of 1.5 nM. Betrixaban shows antithrombotic effect.
|
-
- HY-N0320
-
-
- HY-B0331AS
-
-
- HY-15387
-
-
- HY-107700
-
|
Gavestinel sodium salt
GV 150526
|
iGluR
|
Cardiovascular Disease
|
|
Gavestinel (GV 150526) is a potent, selective, orally active and non-competitive antagonist of NMDA receptor. Gavestinel binds to the glycine site of the NMDA receptor, with a pKi of 8.5. Gavestinel can be used for the research of acute ischemic stroke.
|
-
- HY-12533A
-
|
Disopyramide phosphate
Dicorantil phosphate; SC-7031 phosphate
|
Potassium Channel
Sodium Channel
|
Cardiovascular Disease
|
|
Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action.
|
-
- HY-N0852
-
-
- HY-114671
-
|
Taprostene
CG-4203
|
Prostaglandin Receptor
|
Cardiovascular Disease
|
|
Taprostene (CG-4203) is a synthetic, chemically stable analogue of Prostacyclin (PGI2). Taprostene exhibits endothelium and myocardial protecting actions after acute myocardial ischemia and reperfusion in cats. Taprostene enhances cytoprotective actions, while minimizing unwanted hemodynamic effects.
|
-
- HY-18200
-
|
Atopaxar
E5555; ER-172594-00
|
Protease Activated Receptor (PAR)
|
Cardiovascular Disease
|
|
Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar, an antiplatelet agent, interferes with platelet signaling. Atopaxar can be used for the research of atherothrombotic disease.
|
-
- HY-17369BS
-
-
- HY-U00212
-
-
- HY-N0485
-
|
Liensinine Diperchlorate
|
Autophagy
Mitophagy
|
Cardiovascular Disease
|
|
Liensinine Diperchlorate is a major isoquinoline alkaloid, extracted from the seed embryo of Nelumbo nucifera Gaertn. Liensinine Diperchlorate inhibits late-stage autophagy/mitophagy through blocking autophagosome-lysosome fusion. Liensinine Diperchlorate has a wide range of biological activities, including anti-arrhythmias, anti-hypertension, anti-pulmonary fibrosis, relaxation on vascular smooth muscle, etc.
|
-
- HY-100312
-
-
- HY-B0612D
-
-
- HY-B0428B
-
-
- HY-108003
-
-
- HY-W016823S
-
-
- HY-B0209
-
-
- HY-P1271A
-
|
Catestatin TFA
|
nAChR
|
Cardiovascular Disease
|
|
Catestatin TFA is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin TFA is an endogenous peptide that regulates cardiac function and blood pressure. Catestatin TFA is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release.
|
-
- HY-128338
-
|
CETP-IN-3
|
CETP
|
Cardiovascular Disease
|
|
CETP-IN-3 (Compound 13) is an small molecule inhibitor of the plasma glycoprotein cholesterol ester transfer protein (CETP), elevating HDL-C through inhibition of CETP. CETP-IN-3 for the CETP inhibitory activity in the scintillation proximity (SPA) and whole plasma assay (WPA) with IC50s of 0.002 μM and 0.06 μM, respectively.
|
-
- HY-A0236A
-
|
Aprindine hydrochloride
|
Potassium Channel
|
Cardiovascular Disease
|
|
Aprindine hydrochloride is a class I-b anti-arrhythmic agent and a?hERG channel blocker with an IC50 of 0.23 μM. Aprindine hydrochloride has inhibitory effects on Na +/Ca 2+ exchanger currents, which is partly responsible for their antiarrhythmic and cardioprotective effects. Aprindine hydrochloride is widely used for trial and ventricular tachyarrhythmias research research.
|
-
- HY-122819
-
-
- HY-W010696
-
|
Reverse T3
3′,5′,3-Triiodothyronine
|
Thyroid Hormone Receptor
|
Cardiovascular Disease
|
|
Reverse T3 is a thyroid hormone generated by deiodination of the prohormone thyroxine. Reverse T3 inhibits the increase of sodium current generated by other thyroid hormone analogs in neonatal rat myocytes.
|
-
- HY-17421A
-
-
- HY-100469
-
|
LXRβ agonist-2
|
LXR
|
Cardiovascular Disease
|
|
LXRβ agonist-2 is a highly potent and β-selective liver X receptor (LXRβ) agonist with EC50 of 7 nM, displays 28.5-fold selectivity over LXRα (EC50=200 nM) and used in the treatment of atherosclerosis.
|
-
- HY-130353S
-
|
Desethyl Amiodarone-d4 hydrochloride
|
Potassium Channel
Autophagy
|
Cardiovascular Disease
|
|
Desethyl Amiodarone-d4 (hydrochloride) is the deuterium labeled Desethylamiodarone hydrochloride. Desethylamiodarone hydrochloride (N-desethylamiodarone hydrochloride) is a major active metabolite of Amiodarone. Desethylamiodarone hydrochloride is formed by CYP3A isoenzymes. Amiodarone is an antiarrhythmic agent for inhibition of ATP-sensitive potassium channel with an IC50 of 19.1 μM[1][2][3].
|
-
- HY-N0684
-
-
- HY-N8598
-
|
Caulophine
|
Others
|
Cardiovascular Disease
|
|
Caulophine is a fluoroketone alkaloid isolated from Caulophyllum robustum MAXIM. Caulophine has antioxidant activity and the ability to protect cardiomyocytes from oxidative and ischemic damage, providing potential value for coronary heart disease research.
|
-
- HY-N4142
-
-
- HY-17378
-
-
- HY-119802S
-
-
- HY-105205
-
|
Terlakiren
CP-80,794
|
Renin
|
Cardiovascular Disease
|
|
Terlakiren (CP-80,794) is an orally active inhibitor of renin. Terlakiren inhibits the efficacy of human renin with an IC50 value of 0.7 nM. Terlakiren has potential applications in hypertension.
|
-
- HY-107322A
-
|
Barnidipine
Mepirodipine; YM-09730-5(Free base)
|
Calcium Channel
|
Cardiovascular Disease
|
|
Barnidipine (Mepirodipine) is an L-type calcium antagonist (CaA) with high affinity for [ 3H] initrendipine binding sites (Ki=0.21 nmol/l), has selective action against CaA receptors. Barnidipine (Mepirodipine) is an antihypertensive agent and acts by the reduction of peripheral vascular resistance secondary to its vasodilatory action.
|
-
- HY-B0347
-
|
Lacidipine
|
Calcium Channel
Reactive Oxygen Species
Caspase
Apoptosis
|
Cardiovascular Disease
|
|
Lacidipine is an orally active and highly selective L-type calcium channel blocker that acts on smooth muscle calcium channels, primarily dilates peripheral arteries, reduces peripheral resistance, and has long-lasting anti-hypertensive activity. Lacidipine protects HKCs from apoptosis induced by ATP depletion and recovery by modulating the caspase-3 pathway. Lacidipine can be used in studies of hypertension, atherosclerosis and acute kidney injury (AKI).
|
-
- HY-153492
-
-
- HY-N7991
-
-
- HY-10163AS
-
-
- HY-78237
-
-
- HY-107322
-
|
Barnidipine hydrochloride
Mepirodipine hydrochloride; YM-09730-5
|
Calcium Channel
|
Cardiovascular Disease
|
|
Barnidipine hydrochloride (Mepirodipine hydrochloride) is an L-type calcium antagonist (CaA) with high affinity for [ 3H] initrendipine binding sites (Ki=0.21 nmol/l), has selective action against CaA receptors. Barnidipine hydrochloride (Mepirodipine hydrochloride) is an antihypertensive agent and acts by the reduction of peripheral vascular resistance secondary to its vasodilatory action.
|
-
- HY-121354
-
-
- HY-76006
-
-
- HY-101656
-
-
- HY-110015
-
|
(-)-Chromanol 293B
|
Others
|
Cardiovascular Disease
|
|
(-)-Chromanol 293B is a potent and selective inhibitor of the slow component of delayed rectifier K + current (IKs). (-)-Chromanol 293B can be used for the research of antiarrhythmic.
|
-
- HY-15407A
-
-
- HY-143477
-
-
- HY-101740
-
-
- HY-17004
-
-
- HY-106612
-
-
- HY-B0416
-
-
- HY-B0632
-
|
Diltiazem
|
Calcium Channel
|
Cardiovascular Disease
|
|
Diltiazem is an orally active L-type Ca 2+ channel blocker. Diltiazem shows antihypertensive and antiarrhythmic effects. Diltiazem can be used for the research of cardiac arrhythmia, hypertension, and angina pectoris.
|
-
- HY-B0368A
-
|
Captopril hydrochloride
SQ 14225 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Captopril (SQ 14225) hydrochloride, antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril hydrochloride is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM.
|
-
- HY-B0190
-
-
- HY-B0162S
-
|
Ivabradine-d6
|
HCN Channel
|
Cardiovascular Disease
|
|
Ivabradine-d6 is the deuterium labeled Ivabradine[1]. Ivabradine is a potent and orally active HCN (hyperpolarization-activated cyclic nucleotide-gated) channel blocker that inhibits the cardiac pacemaker current (If). Ivabradine reduces dose-dependently heart rate without modification of blood pressure. Ivabradine shows anticonvulsant, anti-ischaemic and anti-anginal activity[2][3][4][5].
|
-
- HY-101366
-
-
- HY-B0231AS
-
-
- HY-139448
-
-
- HY-12298
-
-
- HY-122365
-
-
- HY-W010451
-
-
- HY-100882
-
-
- HY-14182
-
|
Vernakalant
RSD1235
|
Potassium Channel
|
Cardiovascular Disease
|
|
Vernakalant(RSD-1235) is an investigational mixed ion channel blocker that can terminate acute atrial fibrillation (AF) in humans at 2 to 5 mg/kg and may be more atrial-selective than available agents; in treatment of antiarrhythmic.
|
-
- HY-109193
-
-
- HY-148504
-
-
- HY-P3769
-
-
- HY-14183
-
|
Vernakalant Hydrochloride
RSD1235 hydrochloride
|
Potassium Channel
|
Cardiovascular Disease
|
|
Vernakalant hydrochloride is a mixed voltage- and frequency-dependent Na + and atria-preferred K + channel blocker. IC50 for block by Vernakalant of wild-type and mutant Kv1.5 channels Fractional block is 13.35±0.93 μM, 0.61±0.03 μM, and 1.63±0.09 μM for Kv1.5 channel wt, Kv1.5 channel I508F, Kv1.5 channel T479A, respectively.
|
-
- HY-103045
-
|
CMPD101
|
PKC
ROCK
|
Cardiovascular Disease
|
|
CMPD101 is a potent, highly selective and membrane-permeable small-molecule inhibitor of GRK2/3 with IC50 of 18 nM and 5.4 nM, respectively. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively. CMPD101 can be used for the study of heart failure.
|
-
- HY-17402
-
-
- HY-12724A
-
|
Guanabenz hydrochloride
|
Parasite
Adrenergic Receptor
|
Cardiovascular Disease
|
|
Guanabenz hydrochloride is an orally active α-2-adrenoceptor agonist. Guanabenz hydrochloride has antihypertensive effect and antiparasitic activity. Guanabenz hydrochloride interferes ER stress-signalling and has protective effects in cardiac myocytes. Guanabenz hydrochloride also is used for the research of high blood pressure.
|
-
- HY-123900
-
-
- HY-B1103
-
